Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease

Abstract

Chronic Obstructive Pulmonary Disease (COPD) has significantly contributed to global mortality, with three million deaths reported annually. This impact is expected to increase over the next 40 years, with approximately 5 million people predicted to succumb to COPD-related deaths annually. Immune mechanisms driving disease progression have not been fully elucidated. Airway microbiota have been implicated. However, it is still unclear how changes in the airway microbiome drive persistent immune activation and consequent lung damage. Mechanisms mediating microbiome-immune crosstalk in the airways remain unclear. In this review, we examine how dysbiosis mediates airway inflammation in COPD. We give a detailed account of how airway commensal bacteria interact with the mucosal innate and adaptive immune system to regulate immune responses in healthy or diseased airways. Immune-phenotyping airway microbiota could advance COPD immunotherapeutics and identify key open questions that future research must address to further such translation.

Introduction

Chronic Obstructive Pulmonary Disease (COPD) has been characterized by persistent respiratory symptoms and airflow limitation due to distal airway abnormalities (1). This is usually caused by exposure to noxious particles or gases and is influenced by several host factors (1). Chronic airway inflammation drives small airway changes and destruction of lung parenchymal tissue (2–5). Individuals diagnosed with COPD have varying degrees of chronic bronchitis, distal airway disease, and parenchymal destruction (6). COPD is the third leading cause of death worldwide, with several epidemiologic studies reporting a global prevalence of approximately 11.7% (95% CI: 8.4-15%) (1). According to recent projections, the prevalence is expected to rise over the next 40 years, with approximately 5 million people succumbing to COPD-related death annually (1). The prevalence in Africa has been reported as overall similar to other regions (1, 7).

The mechanisms driving COPD progression have yet to become fully known. The airway microbiome has been implicated in several respiratory diseases, such as COPD, bronchiectasis, and asthma (8). However, it is still unclear how changes in airway microbiota drive persistent immune activation and consequent lung damage in COPD. Whereas N. subflava has been recently demonstrated to drive bronchiectasis, only indirect inference is presently possible for COPD (9, 10). Because of the existence of a well-documented overlap between COPD and bronchiectasis (11–15), it is plausible that N. subflava could contribute to COPD pathogenesis. This, however, needs further investigation. Several studies published elsewhere have also described the airway microbiome in COPD and health (16–30). Dysbiosis (defined as an unhealthy microbial compositional state) in the airways among COPD patients has been associated with disease progression and poor outcomes (23, 29, 31–37). Immune activation of the airways drives COPD progression (38–46). However, it is still unknown how dysbiosis fuels such persistent airway immune activation in COPD. In this review, we examine how dysbiosis may mediate COPD-associated airway inflammation. Although the mechanisms of airway microbiome-immune crosstalk have not been thoroughly investigated, we give a detailed account of how airway commensal bacteria interact with the mucosal innate and adaptive immune system to regulate immune responses in diseased airways. Furthermore, borrowing a page from gut microbiome-immune interactions published elsewhere (47–53), we suggest possible mechanisms worth investigating that could be contributing to COPD disease.

Upon microbial interaction with mucosal immune cells, metabolic and epigenetic changes occur (54–66), inducing immunologic tolerance aimed at minimizing damage potentially arising from responses against invading bacteria (67–69). Several researchers have highlighted the salience of microbiome-mediated immune regulation (50, 70–78). One of the earliest pieces of evidence for this immune regulation was the observation of gene reprogramming following colonization with a bacterial commensal in germ-free mice (79). Such changes are mediated via the activity of bacterial metabolites, discussed in detail in a separate section in this review. Remarkably, most of them (62, 80) attenuate pro-inflammatory responses via epigenetic changes in immune cells, inducing a switch from transcriptionally active to silent chromatin states (67). For instance, butyrate, a short-chain fatty acid, suppresses the activity of NF-kB, consequently inhibiting the production of pro-inflammatory cytokines (81, 82). Similarly, ethionine suppresses the activity of NF-kB and TNFα following stimulation with lipopolysaccharide (LPS) (83), while lactate promotes histone acetylation at the IL10 promoter, enhancing IL10 transcription in macrophages (84). The metabolite deoxycholate alters H3K4me3 and H3K27me3 in bone marrow granulocyte progenitor cells, leading to neutrophil proliferation (85). In germ-free and antibiotic-treated mice, dendritic cell activation and the consequent production of type 1 interferons is impaired, a response driven by reduced levels of H3K4me3 on transcriptional start sites of pro-inflammatory response factors irf-3 and -7 (86). Immune reprogramming has also been noted among adaptive immune cells. Treg cells are induced via the activity of HDAC at the locus of the Foxp3 transcription factor (87–89). In contrast, Th17 differentiation is inhibited (90–92). Comparative analysis of metabolites shows a differing degree of HDAC inhibition, epigenetics, and immune functional consequences (80).

Epigenetic modifications in germ-free mice have been characterized by methylation patterns on inflammatory genes such as those encoding Toll-like receptors, chemokines, and cytokines (93). In neonatal mice, the microbiome induces decreased methylation of the chemokine-encoding gene Cxcl16, which is critical in recruiting iNKT cells into the mucosa (94). Consequently, this change ameliorates inflammation in the gut and the airway mucosa (94). In another scenario, comparative epigenetic analysis of myeloid cells, derived from microbiome-colonized germ-free mice, shows a trimethylation pattern of histone H3 at lysine 4 of the loci of pro-inflammatory genes such as the genes encoding type 1 interferons, which as a result inhibits pro-inflammatory signals (95). Indeed, the role of epigenetics in mucosal immunity has been confirmed by a resultant loss in barrier integrity following the deletion of the histone deacetylase-3 gene from epithelial cells (96). In a nutshell, these findings support the role of microbiota in reprogramming mucosal immune cells, as illustrated in Figures 1, 2. Although the gut microbiome in these studies provides reprogramming signals, available studies further implicate airway microbiome initiating and mediating immune reprogramming locally at the mucosa. As supporting evidence, intranasal administration of a bacterial lysate abrogates experimental allergic asthma by targeting dendritic cells, epithelial cells, and type 2 ILCs (97). Whether similar findings occur in the setting of COPD remains to be investigated.

Figure 1

Figure 2

Mechanistically, microbiome-derived signals such as lipopolysaccharide (LPS) and bacterial DNA stimulate alveolar macrophages and dendritic cells via surface and intracellular sensors, producing several activating signals (chemokines and cytokines) (Figure 3). In the next section, we elaborate on such responses and describe how they activate other immune cellular players, i.e., innate lymphoid cells, γδ-T cells, neutrophils, monocytes, and lymphocytes (Figure 4). A well-coordinated immune response from this cellular network maintains a robust immune barrier at the respiratory mucosa, which preserves the microbial ecology (98, 99). In diseased airways, however, repeated insults such as respiratory infections, cigarette smoke, and particulate matter alter microbiome composition, reducing microbial diversity (100). Consequently, the ensuing dysbiosis triggers immune activation, potentially propagating inflammation and tissue damage observed in COPD (Figure 5) (101, 102). Several observations highlighting this concept have been published. They are summarized here as follows. Infection of distal airways during early childhood with pathogenic bacteria has been reported to cause severe lung damage associated with impaired lung growth and a consequent reduction in lung function (FEV₁/FVC) in adult life (103–105). Although these studies do not establish specific bacterial species orchestrating this damage, several studies report organisms such as S. pneumoniae, H. influenzae, M. catarrhalis, S. aureus, and K. pneumoniae as culprits (106–110). Besides bacterial-induced early childhood-lung injuries and associated COPD in adult life, an interesting hypothesis termed the vicious circle was described, stating that once bacterial pathogens have successfully colonized the airways following impaired mucociliary clearance secondary to a primary insult, they persist, inducing chronic airway inflammation (111). Following the publication of early reports in 2010 describing the lung microbiome (112–115), authors revised the vicious circle to suggest that insults such as tobacco smoke exposure, which impair airway mucosal defenses mediate dysbiosis, leading to dysregulated immune response, further impairment of mucosal defense and ensuing dysbiosis, inducing inflammation and further dysbiosis (99). In distal airways, this inflammation contributes to tissue damage and progressive obstruction, as is the case for P. aeruginosa and N. subflava (9, 116, 117). These effects are mediated via the release of bacterial outer membrane vesicles harboring extracellular products, such as LPS, a potent inflammatory stimulus demonstrated by earlier studies to induce lung emphysema in hamsters (118). Several COPD human studies have supported this hypothesis, showing that bacterial colonization of the airways induces inflammation (111, 115–117, 119–121) and impairs lung function (FEV₁) (122).

Figure 3

Figure 4

Figure 5

Airway bacterial colonization

Airway mucosa houses niche-specific bacterial communities varying in biomass density and diversity as one transition from the upper to lower respiratory tract (123). A physiological gradient primarily drives this difference as a consequence of a gradual increase in the relative humidity (124) and temperature (125), a decrease in the partial pressure of oxygen (pO₂), an increase in the partial pressure of carbon dioxide (pCO₂), and a gradually increasing pH along the respiratory tract (126, 127). pO2/pCO2 gradient is further determined by airway ventilation and the environmental air quality (126, 127). These physiological parameters determine niche-specific selective growth conditions that ultimately shape the microbial communities along the respiratory tract. Therefore, changes in airway physiological conditions directly impact airway microbial composition. During inhalation, bacteria-containing particles are deposited into the respiratory tract. Particles larger than 10μm in diameter remain in the upper respiratory tract, whereas particles smaller than 1μm in diameter reach the alveolar spaces (128). Pili and fimbriae facilitate the attachment of deposited bacteria on the respiratory mucosa (129). Most bacteria fail to attach to the mucosa and are cleared via mucociliary action of the respiratory tract (130); some become neutralized by mucosal surface IgA (131, 132) while others are broken down by mucosal antimicrobial peptides (133). The implication of these immune protective mechanisms in COPD is further elaborated in separate sections. Successfully attached bacteria colonize the airway mucosa, replicating rapidly to establish dense biological niches along the respiratory tract (134) (Figure 3). These bacteria thrive in well-balanced ecosystems, reaching saturation above which competition for space and nutrients limits their growth (135–142). Under physiological conditions, an ecosystem characterized by high bacterial numbers and diversity promotes the utilization of a versatile pool of metabolites. It favors competition for nutrients (135–142), making it difficult for pathogenic bacteria to invade and colonize these niches. In diseased airways, deranged physiological conditions promote the overgrowth of specific bacterial species, decreasing community complexity and increasing preference for the consumption of particular metabolites (129). As a result, reduced competition for nutrients makes it easier for pathogenic bacteria to survive and colonize the respiratory mucosa (143, 144).

Similarly, the depletion of specific bacterial species, for instance, following prolonged antibiotic use, reduces pressure on the ecosystem, creating space and nutrients for other bacterial species to invade and colonize the mucosal field (145). Successful colonization and subsequent mucosal invasion by pathogenic micro-organisms trigger immune activation, inflammation, tissue damage, and further dysbiosis, creating a positive feedback loop that sustains airway inflammation. Evidence from several human airway microbiome studies summarized in a recently published multi-omics meta-analysis supports dysbiosis in inducing immune activation, inflammation, and tissue damage. Although the role of airway microbiome in COPD causation cannot be directly deduced, these findings show a difference in the bacterial communities in healthy and diseased states (24). During the early stages of COPD, airways are predominantly colonized with H. influenzae, M. catarrhalis, and S. pneumoniae. These bacterial species drive inflammation and tissue damage as previously described (111, 115–117, 119–121). Mechanisms of tissue damage induced by these bacteria are discussed further in the following sections. In advanced disease, impaired mucosal defense and reduced O₂ tension in the airways favor the growth of P. aeruginosa, which promotes further inflammation and a vicious circle of tissue damage (146). Exposure and successful airway colonization by new strains of these bacteria trigger inflammation associated with exacerbation (108, 110, 146, 147) and impaired lung function (122).

Cell-to-cell communication between microbes also influences composition along the respiratory mucosa (134) (Figure 3). Interaction between different bacterial species along the airway mucosa determines microbial diversity with implications for COPD (108). Interspecies interactions have been observed among COPD patients colonized with bacterial species such as H. influenzae, M. catarrhalis, S. pneumoniae, and P. aeruginosa (110). Their composition significantly varies as individuals transition from stable disease to COPD exacerbation (147). In stable COPD, S. pneumoniae enrichment positively correlates with H. influenzae enrichment, while P. aeruginosa enrichment negatively correlates with H. influenzae and M. catarrhalis and positively correlates with S. pneumoniae enrichment (108). In the exacerbation state, the relationship between S. pneumoniae and H. influenzae enrichment disappears with the persistence of a correlation between P. aeruginosa, H. influenzae, and M. catarrhalis (108). These observations reveal extensive bacterial interactions among many unculturable bacterial species colonizing the airways. Most likely, this complex interaction is driven by underlying bacterial cell-to-cell communication as individual species establish their niche in the airways. Studies describing the molecular basis of this interaction in the airways are limited. A few illustrate bacterial interactions between selected species following nasopharyngeal colonization (110, 148–151). As described below, extensive studies performed on the gut microbiome illuminate these molecular mechanisms. We believe these pathways are shared. Gut microbiome studies have described bacterial species which directly inhibit other species within the same ecological niche through the secretion of antimicrobial peptides and lytic enzymes. Mechanistically, these factors impede the growth of adjacent bacterial cells via inhibition of peptidoglycan wall synthesis, pore formation, bacterial lysis, and nucleic acid degradation (152). A group of AMPs termed bacteriocins such as microcin, thuricin, and lantibiotics inhibit gram-negative bacteria such as E.coli, S. enterica, C. difficile, and E. faecalis (153–156). Other bacterial species deploy Type VI secretion system (T6SS) through quorum sensing to transport toxic cargo into their micro-environment or other bacterial cells (157–159). Consequently, this kills potentially pathogenic bacteria, maintaining a balanced ecosystem in the respiratory mucosa. For instance, the uptake of nucleic acids from commensal Neisseria species induces cell death of pathogenic N. gonorrhea (160). This is caused by the misrecognition of the DNA’s methylation pattern in N. gonorrhea (160). Similarly, the injection of a defective enzyme into a nearby bacterial cell by P. aeruginosa depletes the target cell’s ATP resulting in microbial cell death (161). B. fragilis secretes a ubiquitin-like protein via T6SS with potent inhibitory activity against coresident strains of B. fragilis (162). Besides secretion systems, bacteria utilize nanotubes to transport plasmids from bacterium to bacterium and extract nutrients such as iron from mammalian host cells (163, 164). As previously stated, a few airway microbiome studies have reported such complex bacterial ecosystem behavior. We hope that with the advent of enriched microbiology culture techniques such as mucin-enriched media, detailed investigations focusing on cell-to-cell interactions between airway bacterial species can be pursued. Such interactions occur in the respiratory mucosa shaping the airway microbiome. As elaborated previously, in diseased airways, the depletion of a single commensal species promotes the replication of another potentially pathogenic species. Disruption of such a balance in the ecosystem consequently triggers and sustains mucosal inflammation and bystander tissue damage (147) (Figures 3–5), as detailed in the following sections. This phenomenon has been described in COPD when the distal airway is colonized with bacterial species such as P. aeruginosa, depleting species such as H. influenzae and M. catarrhalis, and enriching other bacteria such as S. pneumoniae. We believe that the differential changes in the abundance of unculturable bacterial species inhabiting the airway following colonization with new strains or species occur, driving dysbiosis, which triggers acute inflammation associated with exacerbation (108, 110, 146, 147). Other possibly interacting bacteria that induce exacerbations, including Chlamydia spp, L. pneumophilia, Mycoplasma spp, and Non-typable H. influenzae, have been described elsewhere to drive immune inflammation (165)

Microbiome-derived metabolites

A recent focus and comprehensive investigation of the microbiome metabolites, geared towards illuminating microbiome cell-to-cell communication and microbe-host cell immune crosstalk, has drastically improved our understanding of the mechanisms of microbiome mediated immune-modulation in health or dysregulation in disease. Microbial metabolites and their receptors have been described in detail elsewhere (80, 166, 167). Worth mentioning are metabolites of carbohydrates, amino acids, lipids, bile acids, and nucleic acids. In-depth characterization of microbial species based on their ability to produce specific metabolites shows that members of the Bacteroidetes phylum are good producers of acetate (C2) and propionate (C3). In contrast, Firmicutes are efficient producers of butyrate (C4). Other molecules, such as lactate and succinate, are converted to propionate (C3) by several species (168–173). C1-C4 molecules comprise the classical short-chain fatty acids (SCFAs). They can be transported systemically from their production site to other sites, for instance, from the gut to the liver, muscles, lungs, and brain, acting in an endocrine manner (80). These metabolites act on cognate G protein-coupled receptors (GPR43, GPR41, GPR109A, and Olfr78) (174, 175), widely distributed on several immune cells including but not limited to epithelial cells, neutrophils, macrophages, and dendritic cells to induce immune responses (176–180). Signaling via these GPRs generates pro-inflammatory responses via activation of MAP/PI3K kinases and mTOR (181). Anti-inflammatory responses are also generated when intracellular β-arrestins are engaged, inhibiting NF-kB (182–184). Both GPR41 and 43 promote proinflammatory responses, whereas only GPR43 can alternatively generate an anti-inflammatory signal (182–184). It is yet to become known which pathways are preferentially selected by SCFAs. To achieve an efficient immune modulatory program, phased engagement of both receptors would be expected to occur under physiological conditions. Failure of this to happen most likely, results in immune dysregulation, as could be the case for airway dysbiosis. As previously described, SCFAs induce epigenetic changes reprogramming mucosal immune cells to tolerate commensal bacteria.

In dysbiosis, SCFAs induce several defense mechanisms aimed at maintaining mucosal integrity, such as goblet cell activation, mucus hypersecretion (185, 186), replenishment of mucosal surface IgA levels (187–191), production of RegIIIγ (192) and NLRP3 inflammasome activation with the secretion of pro-inflammatory cytokines (193). Whereas these mechanisms have been demonstrated in the gut, parallel mechanisms could exist in the airways. Due to limited data supporting airway accumulation of SCFAs (194), the direct role of SCFAs on airway mucosal immune response cannot be deduced. Several investigators argued that peripheral immune cell activation and subsequent recruitment into the airways drove immune crosstalk (194). Indeed, several studies confirmed this hypothesis. Using animal models, authors demonstrated that the systemic effects of SCFAs were mediated via the bone marrow in a mechanism similar to trained immunity (195–199). In an allergic airway inflammation model, systemic acetate and propionate induced the production of macrophage and dendritic cell progenitor cells (MDPs) as well as common dendritic cell progenitor cells (CDPs) in the bone marrow, which subsequently migrated to the airways to form mature DCs (200–205). In another study, it was demonstrated that although the effects of SCFAs on bone marrow were context-dependent, they ultimately primed myeloid cell proliferation and subsequent migration into the airways, modulating immune responses in an airway influenza infection model (200, 206–208). The relevance of this crosstalk in the context of COPD pathogenesis is supported by evidence of the high prevalence of pulmonary impairment among individuals with chronic inflammatory bowel disease (50%) and individuals with irritable bowel syndrome (33%). Additionally, individuals with COPD are 2 to 3 times more likely to be diagnosed with irritable bowel disease and increased intestinal permeability (209–211). These observations warrant further investigation to underpin mechanisms of lung damage secondary to SCFAs.

Besides carbohydrate metabolism, other genera such as Clostridium, Bacillus, Lactobacillus, and Streptococcus metabolize amino acids including but not limited to glycine, lysine, arginine, leucine, isoleucine, and valine (212). Their biogenic derivatives, such as ammonia, monoamines, polyamines, histamines, agmatine, and cadaverine, induce immune responses via G protein-coupled receptors (213). Furthermore, the metabolism of branched-chain amino acids yields branched-short SCFAs such as isobutyrate, valerate, and isovalerate, which like C4 molecules, induce histone deacetylation, consequently regulating immune responses, as previously elaborated (214, 215). Of critical importance to immune activation and function is the molecule indole produced from tryptophan metabolism (216). Its derivatives, kynurenine, indole-3-acetic acid, and tryptamine, activate the aryl hydrocarbon receptor (AhR) (217), inducing ILC3 and Th17 immune responses (213, 218). A plethora of microbial species metabolizes bile acids as well. Bile acids induce immune cell responses via their receptors (FXR, VDR, PXR, and TGR5) (219, 220). Similarly, these metabolites induce several immune responses to preserve mucosal integrity (221–224) (73, 80, 200). In dysbiosis, metabolites are significantly altered, dysregulating immune activation networks locally and systemically with persistent inflammation. In COPD, this persistent inflammation drives tissue damage with reduced lung function and enhanced respiratory symptoms. Recently, several metabolites such as polyamines, xanthine, glycosphingolipids, and glycerophospholipids have been correlated with enhanced respiratory symptoms and reduced lung function (225). In another recent study, a microbiome-derived metabolic COPD signature comprising 46% lipid, 20% xenobiotic, and 20% amino acid-related metabolites has been reported (29). With recent advances in omics technology, there is a need to further characterize microbiome-derived metabolites as mediators of airway inflammation in COPD.

Local versus systemic immune crosstalk: The role of the gut-lung axis

From the previous section, we can deduce that diverse metabolites’ activity drives the microbiome to impact immune responses locally and systemically. Several authors have referred to this crosstalk as the gut-lung axis to highlight the existence of communication between the gut microbiome and airway immune mucosal system as previously described (194, 226–230). Sufficient data indeed supports the role played by the gut microbiome in driving airway inflammation to cause COPD, as previously described (227, 231, 232). However, the mechanistic underpinnings of the gut-lung axis are yet to be fully deciphered in the context of COPD. Furthermore, whether a bidirectional lung-gut axis exists remains to be answered. Chronic airway diseases such as COPD, asthma, and cystic fibrosis show airway dysbiosis and induce gastrointestinal disturbances such as irritable bowel disease (227). However, this is most likely a result of oral intake of exogenous molecules such as antibiotics and other therapies for chronic respiratory diseases that ultimately cause gut dysbiosis and associated conditions. Mechanistic research utilizing parabiosis animal models is needed to decipher the gut-lung axis fully.

Microbe-host immune interactions

Besides mucosal immune modulation via microbiome derived-metabolites, airway microbiome pathogen-associated molecular patterns (PAMPs) are sensed by the host pattern recognition receptors (PPRs) upon successful attachment to the mucosa (233) (Figure 1, 2). Toll-like receptor TLR2, in conjunction with TLR1/6, recognizes bacterial lipoproteins, whereas TLR4 recognizes bacterial lipopolysaccharide (LPS) (234, 235). Via MyD88-dependent TLR signaling, mucosal epithelial cells secrete AMPs which inhibit bacteria by targeting cytoplasmic and cell-wall components (192, 236) (Figures 1, 2). The significance of such a response has been demonstrated in mouse models where microbial depletion via antibiotic exposure significantly diminishes the mucosal secretion of AMPs (237), with a consequent reduction in the clearance of pathogenic bacteria (237). This is reversed upon mucosal replenishment with a bacterial cocktail, which activates epithelial cells to produce more AMPs (237). In addition to MyD88-dependent activation, sensing of microbial-derived products by nucleotide-binding oligomerization domain-containing receptors such as NOD1, NOD2, and NOD, LRR- and pyrin domain-containing 6 (NLRP6) inflammasome in the epithelial cells sets the pace for a pro-inflammatory signal along the mucosa (238–240). This response restricts mucosal colonization by pathogenic bacteria via secretion of IL-1β and IL-18 cytokines, which are processed from their precursors upon NLRP6 inflammasome activation (238) (Figures 1, 2). In an animal model, authors showed by using mice deficient in IL-18 that activation of the NLRP6 inflammasome induced IL-18 secretion by epithelial cells and prevented gut colonization by pathobionts (238). A recent study has described a microbiome-mediated type I interferon immune response, dependent on cGAS-STING activation irrespective of MyD88-dependent signaling or direct host-bacteria interactions (241) (Figures 1, 2). This study demonstrated that bacterial-derived outer membrane vesicles (OMVs) delivered into distal host cells activated the cGAS-STING-IFN-I axis, promoting clearance of both DNA and RNA viruses (241). Whether such findings can be applied to respiratory mucosa remains to be answered. Given similarities in embryonic origin, structure, and the immune responses mounted in the gut and airway mucosa (227, 242), we believe that a similar response is orchestrated along the airway to maintain mucosal integrity. Indeed, in one animal study, authors demonstrated the induction of a robust and broad innate immune protection of the airways following S. pneumoniae infection, effective against Gram-positive and Gram-negative bacteria and the fungus A. fumigatus (243). The response was characterized by activation of NF-κB, Type I/II IFNs, and Card9-Bcl-Malt pathways associated with upregulated expression of antimicrobial peptides (243). Amidst dysbiosis, sustained immune signaling results in aberrant immune response and inflammation along the mucosa, with bystander tissue damage. Earlier studies demonstrated the tissue-damaging effects of bacterial infection with non-typable H. influenzae using models of nasal turbinate epithelium (244). Similar observations have been recently reported for N. subflava (9). In dysbiosis, bacterial components such as lipoproteins, lipopolysaccharide, and peptidoglycans are released, inducing innate immune responses. These sustain inflammation and tissue damage associated with progressive obstruction observed in COPD.

Mucins and the microbiome

The airway microbiome maintains the integrity of the mucus layer along the respiratory mucosa, preventing massive contact between microbes and the epithelial cells (134). Mucus along the respiratory airway is a major innate immune barrier that, to a significant extent, traps bacteria and clears the airway of these bacteria via mucociliary mechanisms (130). Goblet cells produce a variety of glycosylated mucin proteins along the mucosa (245). Mucins are secreted from the submucosal glandular and goblet cells lining the epithelium (246). Under homeostasis, the airway epithelial lining contains a few goblet cells and a moderate number of submucosal glands (247). Upon activation by bacterial products, environmental toxins, and proinflammatory cytokines, TNF-α, IL-1β, IFN-γ, IL-17A, IL-4, IL-9, and IL-13, goblet cells expand drastically, and submucosal glands increase in frequency, secreting several mucins (248). MUC5AC and 5B are the most predominant among mucin glycoproteins so far described, with MUC2 being the pioneer member characterized (248, 249). Further studies revealed that the gene encoding MUC2 is located next to the MUC5A on chromosome 11p15.5 (250), and its expression occurs early during goblet cell hyperplasia preceding that of the MUC5AC gene (248). Early studies demonstrated that bacterial-derived products such as LPS induced MUC2 expression in vitro using intestinal models via the Ras-MEK1/2-ERK1/2 signaling (251–253). Furthermore, the involvement of TLRs and NF-kB in mucin gene expression has been demonstrated (246). H. influenzae lysates upregulate MUC2 expression via the NF-kB activation (246). Other mechanisms reported to date include signaling via the TGF-β/Smad pathway (246).

Predominantly, mucin-2 is secreted in copious amounts on the mucosa following TLR2/4 and NOD1/2 activation (134). Together with other mucin proteins, mucin 2 forms an impervious layer that prevents massive contact between microbes and the epithelial cells. This barrier prevents potentially exaggerated immune responses. In the well-studied gut microbiome, bacterial species such as B. thetaiotaomicron and F. prausnitzii induce mucin gene expression, protein glycosylation, and mucus-secreting goblet cell differentiation (254). In addition to mucus production, F. prausnitzii maintains mucosal integrity by strengthening epithelial cell tight junctions in an IL-10-dependent manner (255, 256). Therefore, such bacterial species’ depletion reduces mucosal integrity and increases susceptibility to colonization by pathogenic bacteria (Figure 5). Once pathogenic bacteria successfully establish infection in the airways, mucus hypersecretion is induced as part of the acute inflammatory response (257–259). Early studies demonstrated some species, such as H. influenzae, S. pneumoniae, and P. aeruginosa, as potent mucin inducers (260). These studies further described P. aeruginosa as a proteolytic mucin-inducer in contrast to H. influenzae and S. pneumoniae as non-proteolytic mucin-inducers (260). Therefore, it is plausible that in the setting of dysbiosis predominated by known culprits (H. influenzae, M. catarrhalis, S. pneumoniae, and P. aeruginosa), sustained inflammation and mucin gene expression drives mucus production, compounded by impaired mucociliary clearance, distal airway occlusion, and reduced peak expiratory flow, typically observed in patients with chronic bronchitis (257–259). Mucin hypersecretion in COPD patients has been well-described in several studies (246, 261–270). Its accumulation in the airways of COPD patients has been reported as a predictor of mortality, especially among those with a lower baseline FEV₁ (271). Mucus hypersecretion further reduces diffusion and exchange of gases across narrowed airways, worsening an already existing ventilation-perfusion mismatch. Furthermore, in dysbiosis, airway mucociliary activity is severely impaired, further complicating mucus clearance (111, 272–275). Mechanistically, bacterial pathogens induce direct epithelial cell injury, significantly disrupt mucociliary mechanics, and promote hypersecretion of mucus, which creates a conducive environment for pathogens to thrive (111, 272, 276–278).

Antimicrobial peptides and lung damage in microbiome-immune crosstalk

As previously described, one of the outcomes of airway microbiome-immune crosstalk is the secretion of diverse cationic amphipathic peptides, known as antimicrobial peptides (279–281). These molecules kill invading bacterial pathogens in the mucosa, preserving microbial ecology (282, 283). In this review, we discuss two major classes of human-derived antimicrobial peptides: cathelicidins and beta-defensins (284, 285), and further highlight studies implicating such molecules in COPD pathogenesis (286, 287). We acknowledge the existence and role played by other lytic proteins, such as lysozymes (288–291), lactoferrin (292–294), secretory leucocyte protease inhibitor (295–298), cathepsins (299–303), granzymes (304–309), and S100 proteins (310–317). These molecules have been extensively discussed in the referenced articles.

The CAMP gene transcribes cathelicidin (LL-37) in mucosal epithelial cells and other cells of the immune system (318, 319). As elaborated elsewhere, LL-37 induces: (i) microbial killing via cell wall disruption (320–322), (ii) production of pro-inflammatory cytokines such as IL-1β, IL-6, and IL-17 (323–327), and anti-inflammatory cytokine IL-10, which suppresses IL-6, IL-12, TNF, HLA-DR, CD80, CD83, CD86, and CCR7 expression (326, 328, 329). Furthermore, LL-37 induces chemokines CCL2 and CCL7 in IFNγ-dependent manner (323) and polarizes macrophage differentiation towards classical (M1) phenotype and DCs towards cDC1s (330, 331). It also activates the inflammasome in macrophages and monocytes via the P2X7 receptor (332) and induces neutrophilic and eosinophilic migration (319). Other effects, such as angiogenesis, wound healing, and apoptosis, have also been reported (279). It is worth mentioning that, of all cells expressing LL-37, epithelial cells express the molecule only upon activation by inflammatory signals such as infection (318). Vitamin D3 has been demonstrated to regulate the expression of LL-37 via several vitamin D3 response elements located in the CAMP gene promoter region (333). Other than epithelial cells, Vitamin D3 regulates LL-37 expression in monocytes, keratinocytes, and neutrophils in an LPS-synergistic manner via TLR-1/2 in response to bacterial infection (319). Mechanistically, LL-37 binds and activates several extracellular and intracellular receptors (334), inducing pro-inflammatory genes via the activation of transcription factors, NF-kB, CREB1, HIF1α, AP-1/2, and EGR-1 (326, 334, 335).

Besides the known protective effects of LL-37 against invading pathogens at the mucosa, several studies have implicated this peptide in COPD (289, 315, 336, 337, 337, 338, 338, 339, 339, 340, 340, 341, 341, 342, 342, 343, 343, 344, 344, 345, 345, 346, 346–351). Investigators have demonstrated its association with poor lung function (348, 349). In a setting of cigarette-smoke exposure, low levels of LL-37 have been independently associated with lower FEV_1. This decrease in FEV₁ is most significant among individuals with more deficient vitamin D3 (350) and is sustained at 6 and 18 months post-recruitment (351). Whereas low LL-37 was associated with a history of bacterial pneumonia, the inclusion of pneumonia in the adjusted model did not change the findings (350), implying a direct role of LL-37 in affecting lung function. It is still unclear whether increased susceptibility to bacterial infections sets the pace for inflammation and ensuing tissue damage in low LL-37 or whether the peptide directly impacts lung function. However, a recent study favoring the former demonstrates that inhibition of LL-37 promotes bacterial infection, dysbiosis, and inflammation (352). In contrast, earlier in-vitro studies tend to the latter, showing that endogenous cathelicidin (mCRAMP), a mouse ortholog, reduces emphysema severity, probably relating to its anti-inflammatory and healing features (353). Further investigation into the molecular mechanism of LL-37-mediated-COPD pathogenesis is urgently needed. In the setting of well-established COPD, the profile of LL-37 completely reverses, with several studies reporting elevated levels in COPD compared to healthy controls (349, 354–360). This peptide is further elevated during acute COPD exacerbations compared to stable disease due to inflammation secondary to bacterial infection (296), supported by elevated pro-inflammatory cytokines, IL-6, and IL-8 (296). Moreover, in stable COPD, high levels of LL-37 predict acute exacerbation (296, 361). As expected, COPD patients with vitamin D deficiency have significantly lower LL-37 (362–365). This association is even more evident among individuals with acute exacerbation (296, 361). Complex changes in antimicrobial peptides have been reported in dysbiosis among individuals with. For instance, following infection of the airways with a new bacterial strain, LL-37 increases, while lysozyme and SLPI decrease (289). These changes in LL-37 and SLPI are more significant in exacerbation compared to the stable disease (289). Within COPD stages, LL-37 significantly varies from one study to another. Several investigators have reported conflicting results of LL-37 levels based on COPD severity stages (366). Most studies to date have been limited by small sample sizes, heterogeneous sampling (induced versus expectorated sputum versus BAL fluid), and COPD heterogeneity (smoking versus non-smoke-related COPD). This warrants the careful design of adequately powered studies investigating LL-37 as a COPD severity biomarker. Nevertheless, a few studies on COPD stratification based on exacerbation risk shows that the LL-37 is lower in high-risk exacerbators compared to low-risk counterparts (361, 366, 367). Similarly, COPD stratification based on severity shows that LL-37 is significantly reduced in severe disease compared to mild/moderate disease (296, 348). Several authors argue that this observation is most likely driven by a high background of NF-kB activation in severe disease, which has been reported to inhibit LL-37 (366).

A second family of antimicrobial peptides, called defensins, exists and contributes to immune protection against pathogenic bacteria, as described elsewhere (283). Two classes, α- and β-defensins, exist based on the length of their peptides (368, 369). These molecules contribute to granulocyte antimicrobial activity, intestinal mucosal cell defense, and cutaneous host defenses. Six members of the α-defensin include neutrophil peptides (type1-4 α-defensins) secreted by neutrophils, monocytes, lymphocytes, and NK cells. At the same time, types 5 and 6 are expressed and secreted by Paneth cells of the small intestines, epithelial cells of the airways, and gastrointestinal and female reproductive tracts (370). In contrast, β-defensins are widely distributed and expressed in epithelial cells, monocytes, macrophages, and DCs (370). Whereas type 1 β-defensin is constitutively expressed in epithelial cells, type 2 β-defensin is inducible by NF-kB activation (370). Bacteria in the mucosa stimulate the production of both type 3 and 4 β-defensins (371, 372). TNF has also been reported to stimulate the production of type 3 β-defensins. Like LL-37, the secretion of β-defensins produces both pro- and anti-inflammatory signals. For instance, upon activation, neutrophils secrete α-defensins which increase the expression of TNF and IFNγ, with a consequent increase in the expression of FcγRIIB and FcγRI (373). These changes ultimately enhance macrophage phagocytosis. On the contrary, activation of necroptotic neutrophils induces high levels of α-defensins which antagonize the release of nitric oxide and pro-inflammatory cytokines from macrophages, toning down the pro-inflammatory signals (374). Other effects described elsewhere include chemotaxis, angiogenesis, wound healing, antitumor, antifungal, antiviral, and less potent antimicrobial activity (279). β-defensins have been implicated in COPD pathogenesis and disease progression (297, 315, 375–381). Reduced lung function has been associated with increased levels of defensins (380, 382–384). Earlier studies investigating mechanisms of tissue damage in COPD by neutrophils demonstrated that upon neutrophilic infiltration of the airways and activation, neutrophils release defensins which not only play a role in antimicrobial defense but also induce lung tissue injury in addition to other molecules such as serine elastases, cathepsin G and proteinase 3 (375). In in vitro models, these molecules decreased the integrity of the epithelial cell layer and frequency of ciliary beat, as well as inducing mucus hypersecretion and mediating immune modulation (375, 385). The activity of defensins is known to be regulated by the α1-proteinase inhibitor. This molecule competitively blocks defensin’s cytotoxic and stimulatory activity toward epithelial cells (375).

Macrophages and the microbiome

Airway microbiota has been demonstrated to mobilize and reprogram alveolar macrophages, as illustrated in Figures 1, 2. In antibiotic-treated mice, depletion of commensal bacteria induced lower frequencies and numbers of alveolar macrophages. Specifically, these macrophages were reprogrammed to express higher levels of Arg1, CCL24, IL-13, IL-10, IL-6, and IL-1β, consistent with the M2 phenotype (386). These macrophages returned to normal levels following the administration of a consortium of commensal bacteria in the respiratory mucosa of animals previously treated with antibiotics (386). In addition, the microbiome has been shown to potentiate macrophage-bacterial killing and clearance via granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling, reported to be driven by the IL-17/22 axis (387). Models of commensal colonization in antibiotic-treated and germ-free mice have shown that potent NLR-stimulating bacteria in the upper airways promote resistance to airway mucosal colonization by pathogenic bacteria through NOD2 and GM-CSF signaling (387). Antibiotic treatment has also been associated with impaired alveolar macrophage metabolism and defective bactericidal activity (388). Whole-genome mapping of alveolar macrophages revealed upregulation of metabolic pathways in dysbiosis (389), correlating with reduced cellular responsiveness (389). Compared with controls, alveolar macrophages obtained from microbiome-depleted mice showed a diminished capacity to phagocytose bacteria (389). In dysbiosis, pathobionts directly infect alveolar macrophages and use them as vehicles to access the lung interstitium (Figures 3, 4), attracting neutrophils, monocytes, and other inflammatory cells to orchestrate inflammation and lung damage (9, 390). In dysbiosis, the airway microenvironment drives the activation of alveolar macrophages, resulting in mixed phenotypes observed in COPD (391). Colonizing the distal airways with pathogenic bacteria sets an inflammatory tone characterized by increased levels of pro-inflammatory cytokines such as TNF-α and IL-6 (391). The induction of M1/M2 macrophage phenotypes results in a mixed phenotype of airway inflammation and tissue damage driven by classical (i.e., M1) phenotype and airway remodeling and fibrosis driven by alternative (i.e., M2) phenotype. Similar to smoke-induced COPD, other studies report a gradual transition from upregulation of M1 genes to downregulation of the same genes followed by upregulation of M2-related genes (9, 392), which is usually a typical pattern followed from acute inflammation to resolution. Chronic inflammation driven by dysbiosis with a resultant mixed M1/M2 phenotype is the most likely occurrence. M1-driven lung damage is mediated via matrix metalloproteinase (MMP) activity, oxidative stress caused by reactive oxygen and nitrogen species, and many other lytic proteins on parenchymal tissue as elaborated elsewhere (2, 4, 393–396).

Neutrophils and the microbiome

Whereas airway-based human studies demonstrating the direct impact of the microbiome on airway neutrophilic responses are currently scarce, much evidence is inferred from data obtained from intestinal mouse models, which have been extensively reviewed and well-elaborated elsewhere (397). Among highlighted studies, the microbiome has been demonstrated to modulate the neutrophil function and aging via TLR- and MyD88-mediated signaling pathways (398). In a germ-free mouse model, the inflammatory challenge was associated with a reduction in neutrophil recruitment and cytokine production (399), which reversed in the setting of lipopolysaccharide pre-treatment. Notably, this arrest in neutrophilic migration and function was IL-10 dependent (399). In another study, depletion of the microbiome significantly reduced the quantity of circulating aged neutrophils, thus considerably reducing neutrophil-mediated tissue damage (398).

Furthermore, the microbiome has been reported to influence the development and function of neutrophils in several micro-environments (75). Following the development, immature neutrophils demonstrate limited functional quality characterized by reduced proinflammatory activity. However, after microbial sensing via MyD88-dependent pathways, neutrophils become better at phagocytosis and execution (Figure 4) (400, 401). In germ-free and antibiotic-treated mouse models, neutropoiesis in bone marrow is severely impaired, consequently delaying systemic bacterial clearance (401). Similarly, microbiome-derived metabolites such as short-chain fatty acids (SCFAs) drive neutropoiesis via similar mechanisms as previously described (200). In another study, the same metabolites and cell-wall components were demonstrated to induce IL-17 cytokine production from type 3 innate lymphoid cells (ILC3s) and IL-17-producing memory mucosal CD4+T cells, consequently ramping up neutropoiesis via G-CSF production (402). A neutrophilic response at the airway mucosa is critical to eliminate pathogenic micro-organisms, which overcome colonization resistance and successfully invade the mucosal barrier. Airway dysbiosis activates neutrophils via the MyD88-dependent pathway, resulting in NF-KB and MAPK signaling in airway epithelial cells (403–406). Through NETosis (407–409), activated neutrophils release serine-proteinases such as elastases, cathepsin G, and proteinase-3 from primary azurophilic granules. These proteinases cleave elastin, causing lung tissue damage observed in COPD (395, 410–412). Furthermore, secondary and tertiary granules release two metalloproteinases, i.e., collagenases (MMP8) and gelatinases (MMP9), which degrade lung extracellular matrix (395). Persistent neutrophil activation and NETosis orchestrate bystander tissue damage (407–409). (Figure 4, 5). In dysbiosis, LPS and TNF-α induce the production of neutrophilic chemoattractants by activated epithelial cells such as CXCL1 and CXCL8 (413), which promote neutrophilic infiltration into the airways, further driving neutrophilic inflammation and tissue damage (413). As discussed in the proceeding sections, Th17 activation further augments neutrophilic inflammation and tissue damage (414, 415).

Innate lymphoid cells and the microbiome

The innate lymphoid cell family is comprised of cytotoxic cells (the natural killer cells) and non-cytotoxic subsets (referred to as ILC1, ILC2, and ILC3, based on similar nomenclature as T helper cellular sub-phenotypes) (75). Whereas studies investigating the microbiome’s influence on ILCs within the airway mucosa are few, the effect of the microbiome on ILC2 and ILC3 cells has been highlighted (416). In one study, intranasal administration of OM-85 bacterial lysate abrogated experimental allergic asthma by targeting IL-33/ILC2 axis (97). In the next section, we focus on findings from the mouse gut to infer mechanisms influencing ILC-specific immune responses along the airway mucosa. Studies examining the microbiome’s influence on ILCs have concentrated mainly on ILC3s. Recently published reports show that the depletion of ILC3s in mouse models significantly abrogates IL-22 production, with consequent loss of bacterial control within the mucosa, resulting in disease (417). In another study, authors characterized the effect of the gut microbiome on ILC regulatory landscape using antibiotic intervention and germ-free mouse models at the single-cell level. ILCs differentially integrate signals from the microbial microenvironment and generate phenotypic and functional plasticity (418). Furthermore, via ILC3 activation, the microbiome modulates the activity of other immune cells within the mucosa. For instance, (i) microbiome induces commensal-specific CD4+T cells to maintain tolerance at the mucosa (419, 420); (ii) Microbial sensing, inflammasome activation, and the production of IL-1β by macrophages drives GM-CSF secretion by ILC3s, required for macrophage function and induction of tolerance (421); (iii) the production of TNF-β by activated ILC3s drives IgA production at the mucosa (422). (iv) Finally, microbial induction of IL-22 production by ILC3s induces the expression of antimicrobial peptides from epithelial cells required for mucosal host defense (423). It is, therefore, plausible that dysbiosis at the airway mucosa disrupts ILC3-mediated immune regulation, consequently driving aberrant Th17-mediated damage (424) (Figure 5). Although the literature on ILCs in COPD is still minimal (425, 426), the role of ILC3s in COPD warrants investigation since IL-17, its principal cytokine, has already been described as a known driver of neutrophilic inflammation, and individuals with COPD have increased levels of IL-17 (426, 427). Furthermore, IL-17, IL-22, and IL-23-expressing immune cells have been reported in bronchial biopsies from COPD patients (428). Gene expression analysis in lung tissue from COPD patients further provides evidence for the role of ILC3 in COPD (429).

Dendritic cells and the microbiome

Dendritic cells (DCs) are strategically positioned within the airway mucosa, residing in mucosa-associated lymphoid tissue (MALT), such as the Welder’s ring in the upper airways, bronchial lymph nodes in the distal airways, as well as multiple satellites within the lamina propria along the airway mucosal tract (430, 431). Using their dendrites, DCs continuously sample airway bacteria that attach and colonize the mucosa (432–435) or gain access to the MALT via the epithelial tight junction barrier (431, 436–438). Extensive work reviewed elsewhere (431, 438, 439) suggests that depending on the type and degree of microbial exposure, airway DCs induce a wide range of immune responses from immune tolerance induced by plasmacytoid DCs to inflammation induced by conventional DCs (cDCs) (439). Phenotypic characterization of the microbiome based on DC immune responses is still a work in progress. In a recent study investigating the effect of airway microbiome-derived bacterial strains on DC activation, CD4+T cell priming, and cytokine response (440), P. aeruginosa induced high levels of TNF-α, IL−12, and IL-6 from DCs and primed CD4+T cells to secrete IFN-γ and IL-22 compared to S. pneumoniae and R. mucilaginosa (440). In another study, it has been confirmed that R. mucilaginosa inhibits airway immune pro-inflammatory responses via NF-κB-dependent mechanisms (38). This evidence illustrates the impact of dysbiosis on mucosal DC activation and eventual T-cell licensing required to orchestrate inflammation and tissue damage. Studies describing how activated DCs induced by dysbiosis drive COPD pathogenesis are minimal or still a work in progress. The role of activated DCs in driving COPD pathology has been described in the context of cigarette smoke-induced COPD (441–445), which is outside the scope of this review. As described above, bacterial species such as P. aeruginosa, known to predominate in advanced COPD, activate DCs, inducing high levels of TNF-α, IL−12, and IL-6, priming CD4+T cells to secrete IFN-γ and IL-22 (440). Whereas activated DCs secondary to cigarette smoke exposure have been reported to skew adaptive immune response towards Th1 and cytotoxic T cell lymphocyte (CTL) responses (known hallmarks of chronic inflammation in COPD) (442), currently, it’s not known how dysbiosis induces DCs into either type 1 or 2 DCs, which ultimately dictates CD4+T cell phenotypes.

T cells and the microbiome

As previously described, continuous microbial sampling and trafficking by activated DCs, and alveolar macrophages deliver processed microbial antigens to naïve CD4+T and CD8+T cells within MALT and draining lymph nodes (439) (Figures 4, 5). Following microbial-driven immune sensing and activation, the production of IL-12, IL-23, IL-27, and notch ligand by airway DCs, alveolar macrophages, and epithelial cells induces a Th1 response that regulates mucosal colonization by potentially pathogenic bacteria (439). The microbiome is required for optimal mucosal T-cell development, function, and memory. This role has been demonstrated in intestinal mouse models where germ-free mice have been observed to have developmental defects in lymphoid tissues (446, 447). Specifically, these animals display reduced frequencies of mucosal CD4+ and CD8+T cells and decreased numbers of TCR-expressing intraepithelial lymphocytes. Among CD4+T cell phenotypes, microbiome-mediated mucosal inflammation has been strongly linked to aberrant Th17 and suppressed Treg responses in COPD. For instance, enrichment of the lung microbiome with oral taxa is associated with Th17 lung inflammation in COPD (39). Similarly, in bleomycin-induced mouse interstitial pulmonary fibrosis (IPF), airway dysbiosis induces IL-17 cytokine, which ameliorates following either specific airway bacterial depletion or IL-17 blockade. Three commensal bacteria belonging to the genera Bacteroides and Prevotella promote fibrotic pathogenesis through MyD88-dependent IL-17R signaling via bacterial exosomes (448). These findings have been replicated in human studies where Prevotella and Veillonella spp have been associated with enhanced Th17 inflammatory response in COPD (449). In another animal-based study, S. mitis, V. parvula, and P. melaninogenica induced dysbiosis-mediated inflammasome and Th1/Th17 activation with reduced susceptibility to S. pneumoniae. These data imply an immunoprotective role of specific bacterial species in the airways (40). However, chronic Th17 inflammation in persistent dysbiosis promotes lung tissue damage (448). Besides Th17, microbial interaction with mucosal CD4+T cells induces immune tolerance. This process involves several mechanisms extensively described elsewhere (450). We highlight some of these mechanisms here. MyD88-dependent TLR2 activation by microbial-derived PAMPs, such as capsular polysaccharide A from B. fragilis, has been shown to induce the expansion of Foxp3+Tcells within the mucosa (451). Foxp3+T cells drive IL-10 production, facilitating mucosal immune tolerance. B. fragilis have also been shown to deliver antigenic products through bacterial exosomes, which upon phagocytosis by host immune cells via a non-canonical autophagy pathway, induce IL-10 expressing Foxp3+T cells (450, 452). In another mechanism, microbial-induced Tregs promote mucosal memory B or plasma cells’ IgA secretion, epithelial cells’ tight-junction protein expression, and goblet cells’ mucus production in an IL-10-dependent manner (453, 454). This maintains microbial biomass and diversity and facilitates Treg expansion through a symbiotic regulatory loop, preventing overt inflammation (450). Short-chain fatty acids potentiate Foxp3+ cell differentiation and immunomodulatory activity in the gut mucosa as previously discussed (87–89, 455). This evidence implies a tight regulatory role played by mucosal commensal bacteria in maintaining a robust mucosal Treg response. In dysbiosis, however, a heightened Th17 immune response increases TGF-β production with consequent Treg downregulation (456, 457).

B cells, mucosal surface IgA, and COPD

A recently published article describes the role of the microbiome in shaping B-cell immune responses (63). The authors discuss microbiome-driven B cell immune activation, antibody class switching from IgM to IgA, and maintenance of memory B or plasma cells at the mucosal surface (63, 458–460). Although studies referenced in this article are biased toward the gut mucosa, emerging evidence from airway studies confirms the engagement of similar immune responses (461). Upon antigenic encounter at the mucosa, naïve B cells, via antigen-specific B cell receptors, engage the antigen, inducing an activating signal. B cells proliferate and undergo clonal selection, affinity maturation, and class switching within mucosal lymphoid tissue and some in lymph nodes, producing high-quality IgA antibodies (462). This process largely depends on T follicular helper cells (461). A recent study revealed increased expression of the cytokine IL-21 among patients with COPD, primarily in CD4+T cells. IL-21 promotes B cell maturation, antibody affinity maturation, and differentiation into plasma cells. Without co-stimulation, B cells exposed to IL-21 undergo apoptosis which controls bystander B cell immune activation (463). In addition to T cell-dependent help, evidence shows that bacterial products such as LPS can induce human IgM+ B cells to directly class switch to IgA-secreting plasma cells (461). T-independent induction of IgA has been shown to occur in isolated lymphoid follicles and the mucosal lamina propria, generating polyreactive IgA with low affinity for commensal bacteria (462). Upon production by plasma cells, IgA is transported across the mucosal epithelial cells via transcytosis and secreted onto the mucosal surface in a process that requires the binding of dimeric IgA to the polymeric IgA receptor, at least in intestinal models (464). Mucosal surface IgA preserves microbial ecology at the mucosa in several ways. It binds and enchains dividing bacteria, limiting their association with the epithelial cells (465). Selective binding of IgA to some bacterial species also inhibits bacterial cell growth. Studies have demonstrated the induction of sustained commensal-specific IgA memory responses, which become attenuated when a new bacterial strain or species invades the mucosa (458). This evidence implies a continuous IgA repertoire modification to match the dynamic changes in the mucosal microbial communities. This is possible via re-entry and further affinity maturation by somatic hypermutation of existing B cell memory clones in the mucosal lymphoid tissue (466). Bacterial coating with IgM and IgG has also been demonstrated in human intestinal models. Specifically, IgM-secreting plasma cells recognize mucus-dwelling commensals (467). Without IgA, a compensatory IgM response ensues to contain the bacteria (467). It is worth mentioning that microbiome-specific IgA, IgM, and IgG antibodies produced locally can act systemically in similar mechanisms as already described in the gut-lung axis (468). Microbiome-derived metabolites also modulate B cell immune function via induction of epigenetic changes via HDAC inhibitory activity, which induces histone acetylation, enhancing gene expression necessary for B cell differentiation into IgA/G secreting plasma cells (189, 469).

Following the proposition that autoimmunity significantly contributes to COPD pathogenesis, investigators have concentrated their efforts on underpinning the role of B cell immune responses in COPD (470–475). Earlier studies demonstrated the presence of lung lymphoid follicles and elastin-specific antibodies among patients with advanced emphysema (476, 477). Furthermore, unbiased gene expression analysis among emphysema patients revealed a strong link between airway B cells and emphysema (478). This preliminary data provided evidence to investigate further the mechanistic role of B cells in COPD pathogenesis. Studies have additionally demonstrated B cells’ critical role in promoting COPD immunopathology (479–491). For instance, enhanced B cell differentiation into IgA-producing plasma cells has been demonstrated in the airways of COPD patients, where the bronchial epithelial cells primarily provide B cell differentiating signals via the IL-6/IL-6 receptor and BAFF-APRIL/TACI pathways (492). IgA-producing B cells are increased in the distal airways of COPD patients compared to healthy controls and positively correlate with COPD severity scores (461). Results are similar in animal models following infection with P. aeruginosa, a known pathogen in COPD (461). Mechanistically, the direct role of mucosal IgA in inducing lung damage has not yet been fully elucidated (493). The non-inflammatory nature of IgA highly suggests that this molecule is less likely to contribute to COPD pathogenesis directly. However, evidence from known pathological consequences of IgA, such as IgA nephropathy (494), warrants further investigation into the direct role of IgA in COPD pathology. In airway dysbiosis, increased mucosal surface IgA is associated with airway inflammation in COPD (495–499).

Conclusion

This review highlights numerous airway microbiome-mediated immune pathways, mostly in animal models, that drive COPD pathogenesis. Such responses are characterized by alveolar macrophage, dendritic cell, neutrophil, monocyte, innate lymphoid cell, and Th1/Th17 cell activation phenotypes whose interaction with airway epithelial cells culminates into sustained lung inflammation and tissue damage. Although a few human-based COPD studies have also been highlighted, more research is needed to test and validate these findings in human COPD cohorts. Immunophenotyping microbiome habitats has the potential to advance microbiome-based therapeutics. Microbiome-resulting local immunophenotypes are, however, thus far poorly characterized. Accordingly, deep immune phenotyping of the airway host-microbiome interface, possible through multi-omics approaches, may meaningfully inform far more precise interventions in COPD (500).

References

• 1

  VenkatesanP. GOLD report: 2022 update. Lancet Respir Med (2022) 10(2):e20. doi: 10.1016/S2213-2600(21)00561-0

  • CrossRef
  • Google Scholar

• 2

  ChungKAdcockI. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J (2008) 31(6):1334–56. doi: 10.1183/09031936.00018908

  • CrossRef
  • Google Scholar

• 3

  BarbuCIordacheMManM. Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embryol (2011) 52(1):21–7.

  • Google Scholar

• 4

  BarnesPBurneyPSilvermanEKCeliBRVestboJWedzichaJAet al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers (2015) 1:15076. doi: 10.1038/nrdp.2015.76

  • CrossRef
  • Google Scholar

• 5

  FabbriLLuppiFBeghéBRabeK. Complex chronic comorbidities of COPD. Eur Respir J (2008) 31(1):204–12. doi: 10.1183/09031936.00114307

  • CrossRef
  • Google Scholar

• 6

  SaettaMTuratoGMaestrelliPMappCEFabbriLM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 163(6):1304–9. doi: 10.1164/ajrccm.163.6.2009116

  • CrossRef
  • Google Scholar

• 7

  AdeloyeDChuaSLeeCBasquillCPapanaATheodoratouEet al. Global and regional estimates of COPD prevalence: Systematic review and meta–analysis. J Global Health (2015) 5(2). doi: 10.7189/jogh.05.020415

  • CrossRef
  • Google Scholar

• 8

  NataliniJGSinghSSegalLN. The dynamic lung microbiome in health and disease. Nat Rev Microbiol (2022), 1–14. doi: 10.1038/s41579-022-00821-x

  • CrossRef
  • Google Scholar

• 9

  LiLMac AogáinMXuTJaggiTKChanLLQuJet al. Neisseria species as pathobionts in bronchiectasis. Cell Host Microbe (2022) 30(9):1311–27.e8. doi: 10.1016/j.chom.2022.08.005

  • CrossRef
  • Google Scholar

• 10

  SinghSSegalLN. A lung pathobiont story: Thinking outside the koch’s postulate box. Cell Host Microbe (2022) 30(9):1196–8. doi: 10.1016/j.chom.2022.08.012

  • CrossRef
  • Google Scholar

• 11

  O'DonnellAE. Bronchiectasis in patients with COPD: a distinct COPD phenotype? Chest (2011) 140(5):1107–8. doi: 10.1378/chest.11-1484

  • CrossRef
  • Google Scholar

• 12

  Martínez-GarcíaMÁSoler-CataluñaJJSanzYDSerraPCLermaMAVicenteJBet al. Factors associated with bronchiectasis in patients with COPD. Chest (2011) 140(5):1130–7. doi: 10.1378/chest.10-1758

  • CrossRef
  • Google Scholar

• 13

  PatelISVlahosIWilkinsonTMLloyd-OwenSJDonaldsonGCWilksMet al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 170(4):400–7. doi: 10.1164/rccm.200305-648OC

  • CrossRef
  • Google Scholar

• 14

  AgustiACalverleyPCelliBCoxsonHOEdwardsLDLomasDAet al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 11(1):1–14. doi: 10.1186/1465-9921-11-122

  • CrossRef
  • Google Scholar

• 15

  WedzichaJAHurstJR. Structural and functional co-conspirators in chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc (2007) 4(8):602–5. doi: 10.1513/pats.200707-106TH

  • CrossRef
  • Google Scholar

• 16

  WangLHaoKYangTWangC. Role of the lung microbiome in the pathogenesis of chronic obstructive pulmonary disease. Chin Med J (2016) 130(17):2107–11. doi: 10.4103/0366-6999.211452

  • CrossRef
  • Google Scholar

• 17

  TiewPYJaggiTKChanLLChotirmallSH. The airway microbiome in COPD, bronchiectasis and bronchiectasis-COPD overlap. Clin Respir J (2021) 15(2):123–33. doi: 10.1111/crj.13294

  • CrossRef
  • Google Scholar

• 18

  DingKChenJZhanWZhangSChenYLongSet al. Microbiome links cigarette smoke-induced chronic obstructive pulmonary disease and dietary fiber via the gut-lung axis: A narrative review. COPD: J Chronic Obstructive Pulm Dis (2022) 19(1):10–7. doi: 10.1080/15412555.2021.2019208

  • CrossRef
  • Google Scholar

• 19

  DyRSethiS. The lung microbiome and exacerbations of COPD. Curr Opin pulm Med (2016) 22(3):196–202. doi: 10.1097/MCP.0000000000000268

  • CrossRef
  • Google Scholar

• 20

  DicksonRPErb-DownwardJRMartinezFJHuffnagleGB. The microbiome and the respiratory tract. Annu Rev Physiol (2016) 78:481. doi: 10.1146/annurev-physiol-021115-105238

  • CrossRef
  • Google Scholar

• 21

  DitzBChristensonSRossenJBrightlingCKerstjensHAvan den BergeMet al. Sputum microbiome profiling in COPD: beyond singular pathogen detection. Thorax (2020) 75(4):338–44. doi: 10.1136/thoraxjnl-2019-214168

  • CrossRef
  • Google Scholar

• 22

  WangZBafadhelMHaldarKSpivakAMayhewDMillerBEet al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J (2016) 47(4):1082–92. doi: 10.1183/13993003.01406-2015

  • CrossRef
  • Google Scholar

• 23

  EngelMEndesfelderDSchloter-HaiBKublikSGranitsiotisMSBoschettoPet al. Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome. PloS One (2017) 12(7):e0180859. doi: 10.1371/journal.pone.0180859

  • CrossRef
  • Google Scholar

• 24

  WangZYangYYanZLiuHChenBLiangZet al. Multi-omic meta-analysis identifies functional signatures of airway microbiome in chronic obstructive pulmonary disease. ISME J (2020) 14(11):2748–65. doi: 10.1038/s41396-020-0727-y

  • CrossRef
  • Google Scholar

• 25

  YateraKNoguchiSMukaeH. The microbiome in the lower respiratory tract. Respir Invest (2018) 56(6):432–9. doi: 10.1016/j.resinv.2018.08.003

  • CrossRef
  • Google Scholar

• 26

  RichardsonHDickerAJBarclayHChalmersJD. The microbiome in bronchiectasis. Eur Respir Rev. (2019) 28(153). doi: 10.1183/16000617.0048-2019

  • CrossRef
  • Google Scholar

• 27

  BuddenKFShuklaSDRehmanSFBowermanKLKeelySHugenholtzPet al. Functional effects of the microbiota in chronic respiratory disease. Lancet Respir Med (2019) 7(10):907–20. doi: 10.1016/S2213-2600(18)30510-1

  • CrossRef
  • Google Scholar

• 28

  HuangYJErb-DownwardJRDicksonRPCurtisJLHuffnagleGBHanMK. Understanding the role of the microbiome in chronic obstructive pulmonary disease: principles, challenges, and future directions. Trans Res (2017) 179:71–83. doi: 10.1016/j.trsl.2016.06.007

  • CrossRef
  • Google Scholar

• 29

  BowermanKLRehmanSFVaughanALachnerNBuddenKFKimRYet al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat Commun (2020) 11(1):1–15. doi: 10.1038/s41467-020-19701-0

  • CrossRef
  • Google Scholar

• 30

  RussoCColaianniVIeloGValleMSSpicuzzaLMalaguarneraL. Impact of lung microbiota on COPD. Biomedicines (2022) 10(6):1337. doi: 10.3390/biomedicines10061337

  • CrossRef
  • Google Scholar

• 31

  WangZSinghRMillerBETal-SingerRVan HornSTomshoLet al. Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study. Thorax (2018) 73(4):331–8. doi: 10.1136/thoraxjnl-2017-210741

  • CrossRef
  • Google Scholar

• 32

  WangYJWuSSChuJKongXY. Lung microbiome mediates the progression from chronic obstructive pulmonary disease to lung cancer through inflammation. Yi Chuan= Hereditas (2021) 43(1):30–9. doi: 10.16288/j.yczz.20-315

  • CrossRef
  • Google Scholar

• 33

  Leitao FilhoFSAlotaibiNMNganDTamSYangJHollanderZet al. Sputum microbiome is associated with 1-year mortality after chronic obstructive pulmonary disease hospitalizations. Am J Respir Crit Care Med (2019) 199(10):1205–13. doi: 10.1164/rccm.201806-1135OC

  • CrossRef
  • Google Scholar

• 34

  DickerAJHuangJTLonerganMKeirHRFongCJTanBet al. The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. J Allergy Clin Immunol (2021) 147(1):158–67. doi: 10.1016/j.jaci.2020.02.040

  • CrossRef
  • Google Scholar

• 35

  DiaoWShenNDuYErb-DownwardJRSunXGuoCet al. Symptom-related sputum microbiota in stable chronic obstructive pulmonary disease. Int J chronic obstructive pulm dis (2018) 13:2289. doi: 10.2147/COPD.S167618

  • CrossRef
  • Google Scholar

• 36

  RogersGBZainNMMBruceKDBurrLDChenACRivettDWet al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc (2014) 11(4):496–503. doi: 10.1513/AnnalsATS.201310-335OC

  • CrossRef
  • Google Scholar

• 37

  LeeSHLeeYParkJSChoY-JYoonHILeeC-Tet al. Characterization of microbiota in bronchiectasis patients with different disease severities. J Clin Med (2018) 7(11):429. doi: 10.3390/jcm7110429

  • CrossRef
  • Google Scholar

• 38

  RigautsCAizawaJTaylorSLRogersGBGovaertsMCosPet al. Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease. Eur Respir J (2022) 59(5). doi: 10.1183/13993003.01293-2021

  • CrossRef
  • Google Scholar

• 39

  SegalLNClementeJCTsayJ-CJKoralovSBKellerBCWuBGet al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol (2016) 1(5):1–11. doi: 10.1038/nmicrobiol.2016.31

  • CrossRef
  • Google Scholar

• 40

  WuBGSulaimanITsayJ-CJPerezLFrancaBLiYet al. Episodic aspiration with oral commensals induces a MyD88-dependent, pulmonary T-helper cell type 17 response that mitigates susceptibility to streptococcus pneumoniae. Am J Respir Crit Care Med (2021) 203(9):1099–111. doi: 10.1164/rccm.202005-1596OC

  • CrossRef
  • Google Scholar

• 41

  ShuklaSDBuddenKFNealRHansbroPM. Microbiome effects on immunity, health and disease in the lung. Clin Trans Immunol (2017) 6(3):e133. doi: 10.1038/cti.2017.6

  • CrossRef
  • Google Scholar

• 42

  PaudelKRDharwalVPatelVKGalvaoIWadhwaRMalylaVet al. Role of lung microbiome in innate immune response associated with chronic lung diseases. Front Med (2020) 7:554. doi: 10.3389/fmed.2020.00554

  • CrossRef
  • Google Scholar

• 43

  D’AnnaSEBalbiBCappelloFCaroneMDi StefanoA. Bacterial–viral load and the immune response in stable and exacerbated COPD: significance and therapeutic prospects. Int J Chronic Obstructive Pulm Dis (2016) 11:445. doi: 10.2147/COPD.S93398

  • CrossRef
  • Google Scholar

• 44

  HanMKHuangYJLiPumaJJBousheyHABoucherRCCooksonWOet al. Significance of the microbiome in obstructive lung disease. Thorax (2012) 67(5):456–63. doi: 10.1136/thoraxjnl-2011-201183

  • CrossRef
  • Google Scholar

• 45

  SaulerMMcDonoughJEAdamsTSKothapalliNBarnthalerTWerderRBet al. Characterization of the COPD alveolar niche using single-cell RNA sequencing. Nat Commun (2022) 13(1):1–17. doi: 10.1038/s41467-022-28062-9

  • CrossRef
  • Google Scholar

• 46

  BoytonRReynoldsCQuigleyKAltmannD. Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis. Clin Exp Immunol (2013) 171(2):117–23. doi: 10.1111/cei.12003

  • CrossRef
  • Google Scholar

• 47

  IvanovIILittmanDR. Modulation of immune homeostasis by commensal bacteria. Curr Opin Microbiol (2011) 14(1):106–14. doi: 10.1016/j.mib.2010.12.003

  • CrossRef
  • Google Scholar

• 48

  WangQXuR. Data-driven multiple-level analysis of gut-microbiome-immune-joint interactions in rheumatoid arthritis. BMC Genomics (2019) 20(1):1–10. doi: 10.1186/s12864-019-5510-y

  • CrossRef
  • Google Scholar

• 49

  AlexanderMTurnbaughPJ. Deconstructing mechanisms of diet-microbiome-immune interactions. Immunity (2020) 53(2):264–76. doi: 10.1016/j.immuni.2020.07.015

  • CrossRef
  • Google Scholar

• 50

  IchinoheTMiyamaTKawaseTHonjoYKitauraKSatoHet al. Next-generation immune repertoire sequencing as a clue to elucidate the landscape of immune modulation by host–gut microbiome interactions. Front Immunol (2018) 9:668. doi: 10.3389/fimmu.2018.00668

  • CrossRef
  • Google Scholar

• 51

  ZhengDLiwinskiTElinavE. Interaction between microbiota and immunity in health and disease. Cell Res (2020) 30(6):492–506. doi: 10.1038/s41422-020-0332-7

  • CrossRef
  • Google Scholar

• 52

  GunaswethaKSujathaEBramhachariPV. Understanding the interplay between the host immune–microbiome interactions: A state of the art review. Microbiom Hum Health Dis (2021), 123–41. doi: 10.1007/978-981-16-3156-6_8

  • CrossRef
  • Google Scholar

• 53

  TrujilloJLunjaniNRyanDO’MahonyL. Microbiome-immune interactions and relationship to asthma severity. J Allergy Clin Immunol (2022) 149(2):533–4. doi: 10.1016/j.jaci.2021.12.774

  • CrossRef
  • Google Scholar

• 54

  KellyBO'neillLA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res (2015) 25(7):771–84. doi: 10.1038/cr.2015.68

  • CrossRef
  • Google Scholar

• 55

  YoonBROhY-JKangSWLeeEBLeeW-W. Role of SLC7A5 in metabolic reprogramming of human monocyte/macrophage immune responses. Front Immunol (2018) 9:53. doi: 10.3389/fimmu.2018.00053

  • CrossRef
  • Google Scholar

• 56

  BasitFMathanTSanchoDDe VriesIJM. Human dendritic cell subsets undergo distinct metabolic reprogramming for immune response. Front Immunol (2018) 9:2489. doi: 10.3389/fimmu.2018.02489

  • CrossRef
  • Google Scholar

• 57

  MichaeloudesCBhavsarPKMumbySXuBHuiCKMChungKFet al. Role of metabolic reprogramming in pulmonary innate immunity and its impact on lung diseases. J Innate Immun (2020) 12(1):31–46. doi: 10.1159/000504344

  • CrossRef
  • Google Scholar

• 58

  KrautkramerKAKreznarJHRomanoKAVivasEIBarrett-WiltGARabagliaMEet al. Diet-microbiota interactions mediate global epigenetic programming in multiple host tissues. Mol Cell (2016) 64(5):982–92. doi: 10.1016/j.molcel.2016.10.025

  • CrossRef
  • Google Scholar

• 59

  PeeryRCPammiMClaudEShenL. Epigenome–a mediator for host-microbiome crosstalk. Semin Perinatol (2021) 45. doi: 10.1016/j.semperi.2021.151455

  • CrossRef
  • Google Scholar

• 60

  Dominguez-AndresJNeteaMG. Long-term reprogramming of the innate immune system. J leukoc Biol (2019) 105(2):329–38. doi: 10.1002/JLB.MR0318-104R

  • CrossRef
  • Google Scholar

• 61

  ShenderovBA. The human microbiota and chronic disease: dysbiosis as a cause of human pathology. Human Microbiota Chronic Dis: Dysbiosis Cause Human Pathol (2016) 17:179. doi: 10.1002/9781118982907.ch11

  • CrossRef
  • Google Scholar

• 62

  AmatullahHJeffreyKL. Epigenome-metabolome-microbiome axis in health and IBD. Curr Opin Microbiol (2020) 56:97–108. doi: 10.1016/j.mib.2020.08.005

  • CrossRef
  • Google Scholar

• 63

  McCoyKDBurkhardRGeukingMB. The microbiome and immune memory formation. Immunol Cell Biol (2019) 97(7):625–35. doi: 10.1111/imcb.12273

  • CrossRef
  • Google Scholar

• 64

  SaeedSQuintinJKerstensHHRaoNAAghajanirefahAMatareseFet al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. science (2014) 345(6204):1251086. doi: 10.1126/science.1251086

  • CrossRef
  • Google Scholar

• 65

  ChengS-CQuintinJCramerRAShepardsonKMSaeedSKumarVet al. mTOR-and HIF-1α–mediated aerobic glycolysis as metabolic basis for trained immunity. Science (2014) 345(6204):1250684. doi: 10.1126/science.1250684

  • CrossRef
  • Google Scholar

• 66

  ZhouLLinQSonnenbergGF. Metabolic control of innate lymphoid cells in health and disease. Nat Metab (2022) 4:1650–9. doi: 10.1038/s42255-022-00685-8

  • CrossRef
  • Google Scholar

• 67

  BandyopadhayaATsurumiAMauraDJeffreyKLRahmeLG. A quorum-sensing signal promotes host tolerance training through HDAC1-mediated epigenetic reprogramming. Nat Microbiol (2016) 1(12):1–9. doi: 10.1038/nmicrobiol.2016.174

  • CrossRef
  • Google Scholar

• 68

  AyresJSSchneiderDS. Tolerance of infections. Annu Rev Immunol (2012) 30:271–94. doi: 10.1146/annurev-immunol-020711-075030

  • CrossRef
  • Google Scholar

• 69

  SoaresMPGozzelinoRWeisS. Tissue damage control in disease tolerance. Trends Immunol (2014) 35(10):483–94. doi: 10.1016/j.it.2014.08.001

  • CrossRef
  • Google Scholar

• 70

  ButlerMICryanJFDinanTG. Man and the microbiome: a new theory of everything? Annu Rev Clin Psychol (2019) 15:371–98. doi: 10.1146/annurev-clinpsy-050718-095432

  • CrossRef
  • Google Scholar

• 71

  FischbachMA. Microbiome: focus on causation and mechanism. Cell (2018) 174(4):785–90. doi: 10.1016/j.cell.2018.07.038

  • CrossRef
  • Google Scholar

• 72

  LozuponeCA. Unraveling interactions between the microbiome and the host immune system to decipher mechanisms of disease. Msystems (2018) 3(2):e00183–17. doi: 10.1128/mSystems.00183-17

  • CrossRef
  • Google Scholar

• 73

  LevyMBlacherEElinavE. Microbiome, metabolites and host immunity. Curr Opin Microbiol (2017) 35:8–15. doi: 10.1016/j.mib.2016.10.003

  • CrossRef
  • Google Scholar

• 74

  LevastBLiZMadrenasJ. The role of IL-10 in microbiome-associated immune modulation and disease tolerance. Cytokine (2015) 75(2):291–301. doi: 10.1016/j.cyto.2014.11.027

  • CrossRef
  • Google Scholar

• 75

  ThaissCAZmoraNLevyMElinavE. The microbiome and innate immunity. Nature (2016) 535(7610):65–74. doi: 10.1038/nature18847

  • CrossRef
  • Google Scholar

• 76

  LinT-LShuC-CChenY-MLuJ-JWuT-SLaiW-Fet al. Like cures like: pharmacological activity of anti-inflammatory lipopolysaccharides from gut microbiome. Front Pharmacol (2020) 11:554. doi: 10.3389/fphar.2020.00554

  • CrossRef
  • Google Scholar

• 77

  KuipersFde BoerJFStaelsB. Microbiome modulation of the host adaptive immunity through bile acid modification. Cell Metab (2020) 31(3):445–7. doi: 10.1016/j.cmet.2020.02.006

  • CrossRef
  • Google Scholar

• 78

  ShindeTVemuriRShastriSPereraAPGondaliaSVBealeDJet al. Modulating the microbiome and immune responses using whole plant fibre in synbiotic combination with fibre-digesting probiotic attenuates chronic colonic inflammation in spontaneous colitic mice model of IBD. Nutrients (2020) 12(8):2380. doi: 10.3390/nu12082380

  • CrossRef
  • Google Scholar

• 79

  HooperLVWongMHThelinAHanssonLFalkPGGordonJI. Molecular analysis of commensal host-microbial relationships in the intestine. Science (2001) 291(5505):881–4. doi: 10.1126/science.291.5505.881

  • CrossRef
  • Google Scholar

• 80

  KimCH. Immune regulation by microbiome metabolites. Immunology (2018) 154(2):220–9. doi: 10.1111/imm.12930

  • CrossRef
  • Google Scholar

• 81

  ChangPVHaoLOffermannsSMedzhitovR. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci (2014) 111(6):2247–52. doi: 10.1073/pnas.1322269111

  • CrossRef
  • Google Scholar

• 82

  ParkJWKimHYKimMGJeongSYunC-HHanSH. Short-chain fatty acids inhibit staphylococcal lipoprotein-induced nitric oxide production in murine macrophages. Immune netw (2019) 19(2). doi: 10.4110/in.2019.19.e9

  • CrossRef
  • Google Scholar

• 83

  RöthDChiangAJHuWGugiuGBMorraCNVersalovicJet al. Two-carbon folate cycle of commensal lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation. FASEB J (2019) 33(3):3536–48. doi: 10.1096/fj.201801848R

  • CrossRef
  • Google Scholar

• 84

  HeimCEBoschMEYamadaKJAldrichALChaudhariSSKlinkebielDet al. Lactate production by staphylococcus aureus biofilm inhibits HDAC11 to reprogramme the host immune response during persistent infection. Nat Microbiol (2020) 5(10):1271–84. doi: 10.1038/s41564-020-0756-3

  • CrossRef
  • Google Scholar

• 85

  BurgessSLLeslieJLUddinJOaklandDNGilchristCMoreauGBet al. Gut microbiome communication with bone marrow regulates susceptibility to amebiasis. J Clin Invest (2020) 130(8):4019–24. doi: 10.1172/JCI133605

  • CrossRef
  • Google Scholar

• 86

  SchauppLMuthSRogellLKofoed-BranzkMMelchiorFLienenklausSet al. Microbiota-induced type I interferons instruct a poised basal state of dendritic cells. Cell (2020) 181(5):1080–96.e19. doi: 10.1016/j.cell.2020.04.022

  • CrossRef
  • Google Scholar

• 87

  FurusawaYObataYFukudaSEndoTANakatoGTakahashiDet al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature (2013) 504(7480):446–50. doi: 10.1038/nature12721

  • CrossRef
  • Google Scholar

• 88

  ArpaiaNCampbellCFanXDikiySvan der VeekenJDeroosPet al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature (2013) 504(7480):451–5. doi: 10.1038/nature12726

  • CrossRef
  • Google Scholar

• 89

  SmithPMHowittMRPanikovNMichaudMGalliniCABohlooly-yMet al. The microbial metabolites, short-chain fatty acids, regulate colonic treg cell homeostasis. Science (2013) 341(6145):569–73. doi: 10.1126/science.1241165

  • CrossRef
  • Google Scholar

• 90

  ChenLSunMWuWYangWHuangXXiaoYet al. Microbiota metabolite butyrate differentially regulates Th1 and Th17 cells’ differentiation and function in induction of colitis. Inflamm bowel dis (2019) 25(9):1450–61. doi: 10.1093/ibd/izz046

  • CrossRef
  • Google Scholar

• 91

  ZhangMZhouLWangYDorfmanRGTangDXuLet al. Faecalibacterium prausnitzii produces butyrate to decrease c-myc-related metabolism and Th17 differentiation by inhibiting histone deacetylase 3. Int Immunol (2019) 31(8):499–514. doi: 10.1093/intimm/dxz022

  • CrossRef
  • Google Scholar

• 92

  ZhouLZhangMWangYDorfmanRGLiuHYuTet al. Faecalibacterium prausnitzii produces butyrate to maintain Th17/Treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. Inflamm bowel dis (2018) 24(9):1926–40. doi: 10.1093/ibd/izy182

  • CrossRef
  • Google Scholar

• 93

  TakahashiKSugiYNakanoKTsudaMKuriharaKHosonoAet al. Epigenetic control of the host gene by commensal bacteria in large intestinal epithelial cells. J Biol Chem (2011) 286(41):35755–62. doi: 10.1074/jbc.M111.271007

  • CrossRef
  • Google Scholar

• 94

  OlszakTAnDZeissigSVeraMPRichterJFrankeAet al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science (2012) 336(6080):489–93. doi: 10.1126/science.1219328

  • CrossRef
  • Google Scholar

• 95

  GanalSCSanosSLKallfassCOberleKJohnerCKirschningCet al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity (2012) 37(1):171–86. doi: 10.1016/j.immuni.2012.05.020

  • CrossRef
  • Google Scholar

• 96

  AlenghatTOsborneLCSaenzSAKobuleyDZieglerCGMullicanSEet al. Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasis. Nature (2013) 504(7478):153–7. doi: 10.1038/nature12687

  • CrossRef
  • Google Scholar

• 97

  PivnioukVGimenes-JuniorJAEzehPMichaelAPivnioukOHahnSet al. Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium/IL-33/ILC2 axis. J Allergy Clin Immunol (2022) 149(3):943–56. doi: 10.1016/j.jaci.2021.09.013

  • CrossRef
  • Google Scholar

• 98

  ZhangNHeQ-S. Commensal microbiome promotes resistance to local and systemic infections. Chin Med J (2015) 128(16):2250–5. doi: 10.4103/0366-6999.162502

  • CrossRef
  • Google Scholar

• 99

  MammenMJSethiS. COPD and the microbiome. Respirology (2016) 21(4):590–9. doi: 10.1111/resp.12732

  • CrossRef
  • Google Scholar

• 100

  DicksonRPMartinezFJHuffnagleGB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet (2014) 384(9944):691–702. doi: 10.1016/S0140-6736(14)61136-3

  • CrossRef
  • Google Scholar

• 101

  HussellTLuiSJaggerCMorganDBrandO. The consequence of matrix dysfunction on lung immunity and the microbiome in COPD. Eur Respir Rev. (2018) 27(148). doi: 10.1183/16000617.0032-2018

  • CrossRef
  • Google Scholar

• 102

  ReibmanJHsuYChenLCBleckBGordonT. Airway epithelial cells release MIP-3α/CCL20 in response to cytokines and ambient particulate matter. Am J Respir Cell Mol Biol (2003) 28(6):648–54. doi: 10.1165/rcmb.2002-0095OC

  • CrossRef
  • Google Scholar

• 103

  BarkerDJGodfreyKFallCOsmondCWinterPShaheenS. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. Br Med J (1991) 303(6804):671–5. doi: 10.1136/bmj.303.6804.671

  • CrossRef
  • Google Scholar

• 104

  ShaheenSOBarkerDShiellAWCrockerFJWieldGAHolgateST. The relationship between pneumonia in early childhood and impaired lung function in late adult life. Am J Respir Crit Care Med (1994) 149(3):616–9. doi: 10.1164/ajrccm.149.3.8118627

  • CrossRef
  • Google Scholar

• 105

  JohnstonIDStrachanDPAndersonHR. Effect of pneumonia and whooping cough in childhood on adult lung function. New Engl J Med (1998) 338(9):581–7. doi: 10.1056/NEJM199802263380904

  • CrossRef
  • Google Scholar

• 106

  VuoriEPeltolaHKallioMJLeinonenMHedmanKgroup S-Ts. Etiology of pneumonia and other common childhood infections requiring hospitalization and parenteral antimicrobial therapy. Clin Infect dis (1998) 27(3):566–72. doi: 10.1086/514697

  • CrossRef
  • Google Scholar

• 107

  RudanIBoschi-PintoCBiloglavZMulhollandKCampbellH. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ (2008) 86:408–16B. doi: 10.2471/BLT.07.048769

  • CrossRef
  • Google Scholar

• 108

  JacobsDMOchs-BalcomHMZhaoJMurphyTFSethiS. Lower airway bacterial colonization patterns and species-specific interactions in chronic obstructive pulmonary disease. J Clin Microbiol (2018) 56(10):e00330–18. doi: 10.1128/JCM.00330-18

  • CrossRef
  • Google Scholar

• 109

  PatelISeemungalTWilksMLloyd-OwenSDonaldsonGWedzichaJ. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax (2002) 57(9):759–64. doi: 10.1136/thorax.57.9.759

  • CrossRef
  • Google Scholar

• 110

  SethiSMurphyTF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. New Engl J Med (2008) 359(22):2355–65. doi: 10.1056/NEJMra0800353

  • CrossRef
  • Google Scholar

• 111

  SethiS. Bacterial infection and the pathogenesis of COPD. Chest (2000) 117(5):286S–91S. doi: 10.1378/chest.117.5_suppl_1.286S

  • CrossRef
  • Google Scholar

• 112

  HiltyMBurkeCPedroHCardenasPBushABossleyCet al. Disordered microbial communities in asthmatic airways. PloS One (2010) 5(1):e8578. doi: 10.1371/journal.pone.0008578

  • CrossRef
  • Google Scholar

• 113

  CharlsonESBittingerKHaasARFitzgeraldASFrankIYadavAet al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med (2011) 184(8):957–63. doi: 10.1164/rccm.201104-0655OC

  • CrossRef
  • Google Scholar

• 114

  Erb-DownwardJRThompsonDLHanMKFreemanCMMcCloskeyLSchmidtLAet al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PloS One (2011) 6(2):e16384. doi: 10.1371/journal.pone.0016384

  • CrossRef
  • Google Scholar

• 115

  SethiSMaloneyJGroveLWronaCBerensonCS. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 173(9):991–8. doi: 10.1164/rccm.200509-1525OC

  • CrossRef
  • Google Scholar

• 116

  Garcia-VidalCAlmagroPRomaníVRodriguez-CarballeiraMCuchiECanalesLet al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J (2009) 34(5):1072–8. doi: 10.1183/09031936.00003309

  • CrossRef
  • Google Scholar

• 117

  Martinez-GarcíaMARigauDBarrechegurenMGarcía-OrtegaANuñezAYepezGOet al. Long-term risk of mortality associated with isolation of pseudomonas aeruginosa in COPD: A systematic review and meta-analysis. Int J Chronic Obstructive Pulm Dis (2022) 17:371. doi: 10.2147/COPD.S346294

  • CrossRef
  • Google Scholar

• 118

  StolkJRudolphusADaviesPOsingaDDijkmanJHAgarwalLet al. Induction of emphysema and bronchial mucus cell hyperplasia by intratracheal instillation of lipopolysaccharide in the hamster. J pathol (1992) 167(3):349–56. doi: 10.1002/path.1711670314

  • CrossRef
  • Google Scholar

• 119

  DesaiHEschbergerKWronaCGroveLAgrawalAGrantBet al. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc (2014) 11(3):303–9. doi: 10.1513/AnnalsATS.201310-350OC

  • CrossRef
  • Google Scholar

• 120

  TumkayaMAtisSOzgeCDelialiogluNPolatGKanikA. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med (2007) 101(4):729–37. doi: 10.1016/j.rmed.2006.08.020

  • CrossRef
  • Google Scholar

• 121

  ZhangMLiQZhangX-YDingXZhuDZhouX. Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease. Eur J Clin Microbiol Infect dis (2010) 29(12):1487–93. doi: 10.1007/s10096-010-1027-7

  • CrossRef
  • Google Scholar

• 122

  WilkinsonTMPatelISWilksMDonaldsonGCWedzichaJA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 167(8):1090–5. doi: 10.1164/rccm.200210-1179OC

  • CrossRef
  • Google Scholar

• 123

  ManWHde Steenhuijsen PitersWABogaertD. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol (2017) 15(5):259–70. doi: 10.1038/nrmicro.2017.14

  • CrossRef
  • Google Scholar

• 124

  KeckTLindemannJ. Numerical simulation and nasal air-conditioning. GMS Curr topics otorhinolaryngol Head Neck surg (2010) 9. doi: 10.1097/00005537-200406000-00015

  • CrossRef
  • Google Scholar

• 125

  IngenitoESolwayJMcFaddenEPichurkoBBowmanHMichaelsDet al. Indirect assessment of mucosal surface temperatures in the airways: theory and tests. J Appl Physiol (1987) 63(5):2075–83. doi: 10.1152/jappl.1987.63.5.2075

  • CrossRef
  • Google Scholar

• 126

  WestJB. Regional differences in the lung. Chest (1978) 74(4):426–37. doi: 10.1016/S0012-3692(15)37392-X

  • CrossRef
  • Google Scholar

• 127

  BrunworthJDGargRMahboubiHJohnsonBDjalilianHR. Detecting nasopharyngeal reflux: a novel pH probe technique. Ann Otol Rhinol Laryngol (2012) 121(7):427–30. doi: 10.1177/000348941212100701

  • CrossRef
  • Google Scholar

• 128

  BrownJHCookKNeyFGHatchT. Influence of particle size upon the retention of particulate matter in the human lung. Am J Public Health Nations Health (1950) 40(4):450–80. doi: 10.2105/AJPH.40.4.450

  • CrossRef
  • Google Scholar

• 129

  KlineKAFälkerSDahlbergSNormarkSHenriques-NormarkB. Bacterial adhesins in host-microbe interactions. Cell Host Microbe (2009) 5(6):580–92. doi: 10.1016/j.chom.2009.05.011

  • CrossRef
  • Google Scholar

• 130

  WannerASalathéMO'RiordanTG. Mucociliary clearance in the airways. Am J Respir Crit Care Med (1996) 154(6):1868–902. doi: 10.1164/ajrccm.154.6.8970383

  • CrossRef
  • Google Scholar

• 131

  OhJESongEMoriyamaMWongPZhangSJiangRet al. Intranasal priming induces local lung-resident b cell populations that secrete protective mucosal antiviral IgA. Sci Immunol (2021) 6(66):eabj5129. doi: 10.1126/sciimmunol.abj5129

  • CrossRef
  • Google Scholar

• 132

  LammMENedrudJGKaetzelCSMazanecMB. IgA and mucosal defense. Apmis (1995) 103(1-6):241–6. doi: 10.1111/j.1699-0463.1995.tb01101.x

  • CrossRef
  • Google Scholar

• 133

  BevinsCL. (2007). Antimicrobial peptides: antimicrobial peptides: Ciba foundation symposium 186. In: Novartis Foundation Symposia. Wiley Online Library. doi: 10.1002/9780470514658.ch15

  • CrossRef
  • Google Scholar

• 134

  LeshemALiwinskiTElinavE. Immune-microbiota interplay and colonization resistance in infection. Mol Cell (2020) 78(4):597–613. doi: 10.1016/j.molcel.2020.03.001

  • CrossRef
  • Google Scholar

• 135

  MomoseYHirayamaKItohK. Competition for proline between indigenous escherichia coli and e. coli O157: H7 in gnotobiotic mice associated with infant intestinal microbiota and its contribution to the colonization resistance against e. coli O157: H7. Antonie Van Leeuwenhoek (2008) 94(2):165–71. doi: 10.1007/s10482-008-9222-6

  • CrossRef
  • Google Scholar

• 136

  CurtisMMHuZKlimkoCNarayananSDeberardinisRSperandioV. The gut commensal bacteroides thetaiotaomicron exacerbates enteric infection through modification of the metabolic landscape. Cell Host Microbe (2014) 16(6):759–69. doi: 10.1016/j.chom.2014.11.005

  • CrossRef
  • Google Scholar

• 137

  LeathamMPBanerjeeSAutieriSMMercado-LuboRConwayTCohenPS. Precolonized human commensal escherichia coli strains serve as a barrier to e. coli O157: H7 growth in the streptomycin-treated mouse intestine. Infect immun (2009) 77(7):2876–86. doi: 10.1128/IAI.00059-09

  • CrossRef
  • Google Scholar

• 138

  CassatJESkaarEP. Iron in infection and immunity. Cell Host Microbe (2013) 13(5):509–19. doi: 10.1016/j.chom.2013.04.010

  • CrossRef
  • Google Scholar

• 139

  DeriuELiuJZPezeshkiMEdwardsRAOchoaRJContrerasHet al. Probiotic bacteria reduce salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe (2013) 14(1):26–37. doi: 10.1016/j.chom.2013.06.007

  • CrossRef
  • Google Scholar

• 140

  CerasiMAmmendolaSBattistoniA. Competition for zinc binding in the host-pathogen interaction. Front Cell infect Microbiol (2013) 3:108. doi: 10.3389/fcimb.2013.00108

  • CrossRef
  • Google Scholar

• 141

  GieldaLMDiRitaVJ. Zinc competition among the intestinal microbiota. MBio (2012) 3(4):e00171–12. doi: 10.1128/mBio.00171-12

  • CrossRef
  • Google Scholar

• 142

  LitvakYMonKKNguyenHChanthavixayGLiouMVelazquezEMet al. Commensal enterobacteriaceae protect against salmonella colonization through oxygen competition. Cell Host Microbe (2019) 25(1):128–39.e5. doi: 10.1016/j.chom.2018.12.003

  • CrossRef
  • Google Scholar

• 143

  FonsecaDHandTHanS-JGernerMZaretskyAByrdAet al. Microbiota-dependent sequelae of acute infection compromise tissue-specific immunity. Cell (2015) 163(2):354–66. doi: 10.1016/j.cell.2015.08.030

  • CrossRef
  • Google Scholar

• 144

  ZacharZSavageDC. Microbial interference and colonization of the murine gastrointestinal tract by listeria monocytogenes. Infect immun (1979) 23(1):168–74. doi: 10.1128/iai.23.1.168-174.1979

  • CrossRef
  • Google Scholar

• 145

  Van der WaaijDBerghuis-de VriesJLekkerkerk-Van der WeesJ. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. Epidemiol Infect (1971) 69(3):405–11. doi: 10.1017/S0022172400021653

  • CrossRef
  • Google Scholar

• 146

  MurphyTFBrauerALEschbergerKLobbinsPGroveLCaiXet al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 177(8):853–60. doi: 10.1164/rccm.200709-1413OC

  • CrossRef
  • Google Scholar

• 147

  SethiSEvansNGrantBJMurphyTF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. New Engl J Med (2002) 347(7):465–71. doi: 10.1056/NEJMoa012561

  • CrossRef
  • Google Scholar

• 148

  JacobyPWatsonKBowmanJTaylorARileyTVSmithDWet al. Modelling the co-occurrence of streptococcus pneumoniae with other bacterial and viral pathogens in the upper respiratory tract. Vaccine (2007) 25(13):2458–64. doi: 10.1016/j.vaccine.2006.09.020

  • CrossRef
  • Google Scholar

• 149

  MadhiSAAdrianPKuwandaLCutlandCAlbrichWCKlugmanKP. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by streptococcus pneumoniae–and associated interactions with staphylococcus aureus and haemophilus influenzae colonization–in HIV-infected and HIV-uninfected children. J Infect dis (2007) 196(11):1662–6. doi: 10.1086/522164

  • CrossRef
  • Google Scholar

• 150

  Regev-YochayGDaganRRazMCarmeliYShainbergBDerazneEet al. Association between carriage of streptococcus pneumoniae and staphylococcus aureus in children. Jama (2004) 292(6):716–20. doi: 10.1001/jama.292.6.716

  • CrossRef
  • Google Scholar

• 151

  ChienY-WVidalJEGrijalvaCGBozioCEdwardsKMWilliamsJVet al. Density interactions between streptococcus pneumoniae, haemophilus influenzae and staphylococcus aureus in the nasopharynx of young Peruvian children. Pediatr Infect Dis J (2013) 32(1):72. doi: 10.1097/INF.0b013e318270d850

  • CrossRef
  • Google Scholar

• 152

  KommineniSBretlDJLamVChakrabortyRHaywardMSimpsonPet al. Bacteriocin production augments niche competition by enterococci in the mammalian gastrointestinal tract. Nature (2015) 526(7575):719–22. doi: 10.1038/nature15524

  • CrossRef
  • Google Scholar

• 153

  SchambergerGPDiez-GonzalezF. Selection of recently isolated colicinogenic escherichia coli strains inhibitory to escherichia coli O157: H7. J Food protect (2002) 65(9):1381–7. doi: 10.4315/0362-028X-65.9.1381

  • CrossRef
  • Google Scholar

• 154

  Sassone-CorsiMNuccioS-PLiuHHernandezDVuCTTakahashiAAet al. Microcins mediate competition among enterobacteriaceae in the inflamed gut. Nature (2016) 540(7632):280–3. doi: 10.1038/nature20557

  • CrossRef
  • Google Scholar

• 155

  ReaMCSitCSClaytonEO'ConnorPMWhittalRMZhengJet al. A posttranslationally modified bacteriocin with a narrow spectrum of activity against clostridium difficile. Proc Natl Acad Sci (2010) 107(20):9352–7. doi: 10.1073/pnas.0913554107

  • CrossRef
  • Google Scholar

• 156

  KimSGBecattiniSMoodyTUShliahaPVLittmannERSeokRet al. Microbiota-derived lantibiotic restores resistance against vancomycin-resistant enterococcus. Nature (2019) 572(7771):665–9. doi: 10.1038/s41586-019-1501-z

  • CrossRef
  • Google Scholar

• 157

  ZhaoWCaroFRobinsWMekalanosJJ. Antagonism toward the intestinal microbiota and its effect on vibrio cholerae virulence. Science (2018) 359(6372):210–3. doi: 10.1126/science.aap8775

  • CrossRef
  • Google Scholar

• 158

  BaslerMMekalanosJ. Type 6 secretion dynamics within and between bacterial cells. Science (2012) 337(6096):815. doi: 10.1126/science.1222901

  • CrossRef
  • Google Scholar

• 159

  RossBDVersterAJRadeyMCSchmidtkeDTPopeCEHoffmanLRet al. Human gut bacteria contain acquired interbacterial defence systems. Nature (2019) 575(7781):224–8. doi: 10.1038/s41586-019-1708-z

  • CrossRef
  • Google Scholar

• 160

  KimWJHigashiDGoytiaMRendónMAPilligua-LucasMBronnimannMet al. Commensal neisseria kill neisseria gonorrhoeae through a DNA-dependent mechanism. Cell Host Microbe (2019) 26(2):228–39.e8. doi: 10.1016/j.chom.2019.07.003

  • CrossRef
  • Google Scholar

• 161

  AhmadSWangBWalkerMDTranH-KRStogiosPJSavchenkoAet al. An interbacterial toxin inhibits target cell growth by synthesizing (p) ppApp. Nature (2019) 575(7784):674–8. doi: 10.1038/s41586-019-1735-9

  • CrossRef
  • Google Scholar

• 162

  Chatzidaki-LivanisMGeva-ZatorskyNComstockLE. Bacteroides fragilis type VI secretion systems use novel effector and immunity proteins to antagonize human gut bacteroidales species. Proc Natl Acad Sci (2016) 113(13):3627–32. doi: 10.1073/pnas.1522510113

  • CrossRef
  • Google Scholar

• 163

  BhattacharyaSBaidyaAKPalRRMamouGGattYEMargalitHet al. A ubiquitous platform for bacterial nanotube biogenesis. Cell Rep (2019) 27(2):334–42.e10. doi: 10.1016/j.celrep.2019.02.055

  • CrossRef
  • Google Scholar

• 164

  PalRRBaidyaAKMamouGBhattacharyaSSocolYKobiSet al. Pathogenic e. coli extracts nutrients from infected host cells utilizing injectisome components. Cell (2019) 177(3):683–96.e18. doi: 10.1016/j.cell.2019.02.022

  • CrossRef
  • Google Scholar

• 165

  SuY-CJalalvandFThegerströmJRiesbeckK. The interplay between immune response and bacterial infection in COPD: focus upon non-typeable haemophilus influenzae. Front Immunol (2018) 9:2530. doi: 10.3389/fimmu.2018.02530

  • CrossRef
  • Google Scholar

• 166

  GarrettWS. Immune recognition of microbial metabolites. Nat Rev Immunol (2020) 20(2):91–2. doi: 10.1038/s41577-019-0252-2

  • CrossRef
  • Google Scholar

• 167

  SkellyANSatoYKearneySHondaK. Mining the microbiota for microbial and metabolite-based immunotherapies. Nat Rev Immunol (2019) 19(5):305–23. doi: 10.1038/s41577-019-0144-5

  • CrossRef
  • Google Scholar

• 168

  MacfarlaneSMacfarlaneGT. Regulation of short-chain fatty acid production. Proc Nutr Soc (2003) 62(1):67–72. doi: 10.1079/PNS2002207

  • CrossRef
  • Google Scholar

• 169

  DerrienMVaughanEEPluggeCMde VosWM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J syst evol Microbiol (2004) 54(5):1469–76. doi: 10.1099/ijs.0.02873-0

  • CrossRef
  • Google Scholar

• 170

  LouisPHoldGLFlintHJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol (2014) 12(10):661–72. doi: 10.1038/nrmicro3344

  • CrossRef
  • Google Scholar

• 171

  LouisPYoungPHoltropGFlintHJ. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA: acetate CoA-transferase gene. Environ Microbiol (2010) 12(2):304–14. doi: 10.1111/j.1462-2920.2009.02066.x

  • CrossRef
  • Google Scholar

• 172

  MorrisonDJPrestonT. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes (2016) 7(3):189–200. doi: 10.1080/19490976.2015.1134082

  • CrossRef
  • Google Scholar

• 173

  KasubuchiMHasegawaSHiramatsuTIchimuraAKimuraI. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients (2015) 7(4):2839–49. doi: 10.3390/nu7042839

  • CrossRef
  • Google Scholar

• 174

  ColosimoDAKohnJALuoPMPiscottaFJHanSMPickardAJet al. Mapping interactions of microbial metabolites with human G-protein-coupled receptors. Cell Host Microbe (2019) 26(2):273–82.e7. doi: 10.1016/j.chom.2019.07.002

  • CrossRef
  • Google Scholar

• 175

  ChenHNweP-KYangYRosenCEBieleckaAAKuchrooMet al. A forward chemical genetic screen reveals gut microbiota metabolites that modulate host physiology. Cell (2019) 177(5):1217–31.e18. doi: 10.1016/j.cell.2019.03.036

  • CrossRef
  • Google Scholar

• 176

  BrownAJGoldsworthySMBarnesAAEilertMMTcheangLDanielsDet al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem (2003) 278(13):11312–9. doi: 10.1074/jbc.M211609200

  • CrossRef
  • Google Scholar

• 177

  NilssonNEKotarskyKOwmanCOldeB. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun (2003) 303(4):1047–52. doi: 10.1016/S0006-291X(03)00488-1

  • CrossRef
  • Google Scholar

• 178

  ThangarajuMCresciGALiuKAnanthSGnanaprakasamJPBrowningDDet al. GPR109A is a g-protein–coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res (2009) 69(7):2826–32. doi: 10.1158/0008-5472.CAN-08-4466

  • CrossRef
  • Google Scholar

• 179

  HustedASTrauelsenMRudenkoOHjorthSASchwartzTW. GPCR-mediated signaling of metabolites. Cell Metab (2017) 25(4):777–96. doi: 10.1016/j.cmet.2017.03.008

  • CrossRef
  • Google Scholar

• 180

  MoritaNUmemotoEFujitaSHayashiAKikutaJKimuraIet al. GPR31-dependent dendrite protrusion of intestinal CX3CR1+ cells by bacterial metabolites. Nature (2019) 566(7742):110–4. doi: 10.1038/s41586-019-0884-1

  • CrossRef
  • Google Scholar

• 181

  ThorburnANMaciaLMackayCR. Diet, metabolites, and “western-lifestyle” inflammatory diseases. Immunity (2014) 40(6):833–42. doi: 10.1016/j.immuni.2014.05.014

  • CrossRef
  • Google Scholar

• 182

  LiMvan EschBCWagenaarGTGarssenJFolkertsGHenricksPA. Pro-and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells. Eur J Pharmacol (2018) 831:52–9. doi: 10.1016/j.ejphar.2018.05.003

  • CrossRef
  • Google Scholar

• 183

  GaoHSunYWuYLuanBWangYQuBet al. Identification of β-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-κB pathways. Mol Cell (2004) 14(3):303–17. doi: 10.1016/S1097-2765(04)00216-3

  • CrossRef
  • Google Scholar

• 184

  KimMHKangSGParkJHYanagisawaMKimCH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology (2013) 145(2):396–406. e10. doi: 10.1053/j.gastro.2013.04.056

  • CrossRef
  • Google Scholar

• 185

  GaudierEJarryABlottiereHDe CoppetPBuisineMAubertJet al. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiology-Gastrointest Liver Physiol (2004) 287(6):G1168–G74. doi: 10.1152/ajpgi.00219.2004

  • CrossRef
  • Google Scholar

• 186

  WillemsenLKoetsierMVan DeventerSVan TolE. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E1 and E2 production by intestinal myofibroblasts. Gut (2003) 52(10):1442–7. doi: 10.1136/gut.52.10.1442

  • CrossRef
  • Google Scholar

• 187

  HooperLVMacphersonAJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol (2010) 10(3):159–69. doi: 10.1038/nri2710

  • CrossRef
  • Google Scholar

• 188

  McGuckinMALindénSKSuttonPFlorinTH. Mucin dynamics and enteric pathogens. Nat Rev Microbiol (2011) 9(4):265–78. doi: 10.1038/nrmicro2538

  • CrossRef
  • Google Scholar

• 189

  KimMQieYParkJKimCH. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe (2016) 20(2):202–14. doi: 10.1016/j.chom.2016.07.001

  • CrossRef
  • Google Scholar

• 190

  WuWSunMChenFCaoATLiuHZhaoYet al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. Mucosal Immunol (2017) 10(4):946–56. doi: 10.1038/mi.2016.114

  • CrossRef
  • Google Scholar

• 191

  TakeuchiTMiyauchiEKanayaTKatoTNakanishiYWatanabeTet al. Acetate differentially regulates IgA reactivity to commensal bacteria. Nature (2021) 595(7868):560–4. doi: 10.1038/s41586-021-03727-5

  • CrossRef
  • Google Scholar

• 192

  NatividadJMHayesCLMottaJ-PJuryJGalipeauHJPhilipVet al. Differential induction of antimicrobial REGIII by the intestinal microbiota and bifidobacterium breve NCC2950. Appl Environ Microbiol (2013) 79(24):7745–54. doi: 10.1128/AEM.02470-13

  • CrossRef
  • Google Scholar

• 193

  MaciaLTanJVieiraATLeachKStanleyDLuongSet al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun (2015) 6(1):1–15. doi: 10.1038/ncomms7734

  • CrossRef
  • Google Scholar

• 194

  DangATMarslandBJ. Microbes, metabolites, and the gut–lung axis. Mucosal Immunol (2019) 12(4):843–50. doi: 10.1038/s41385-019-0160-6

  • CrossRef
  • Google Scholar

• 195

  NeteaMGvan der MeerJW. Trained immunity: an ancient way of remembering. Cell Host Microbe (2017) 21(3):297–300. doi: 10.1016/j.chom.2017.02.003

  • CrossRef
  • Google Scholar

• 196

  NeteaMGDomínguez-AndrésJBarreiroLBChavakisTDivangahiMFuchsEet al. Defining trained immunity and its role in health and disease. Nat Rev Immunol (2020) 20(6):375–88. doi: 10.1038/s41577-020-0285-6

  • CrossRef
  • Google Scholar

• 197

  SchulthessJPandeySCapitaniMRue-AlbrechtKCArnoldIFranchiniFet al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity (2019) 50(2):432–45.e7. doi: 10.1016/j.immuni.2018.12.018

  • CrossRef
  • Google Scholar

• 198

  WattRParkinKMartinoD. The potential effects of short-chain fatty acids on the epigenetic regulation of innate immune memory. Challenges (2020) 11(2):25. doi: 10.3390/challe11020025

  • CrossRef
  • Google Scholar

• 199

  BekkeringSDomínguez-AndrésJJoostenLARiksenNPNeteaMG. Trained immunity: reprogramming innate immunity in health and disease. Annu Rev Immunol (2021) 39:667–93. doi: 10.1146/annurev-immunol-102119-073855

  • CrossRef
  • Google Scholar

• 200

  TrompetteAGollwitzerESYadavaKSichelstielAKSprengerNNgom-BruCet al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med (2014) 20(2):159–66. doi: 10.1038/nm.3444

  • CrossRef
  • Google Scholar

• 201

  LandsmanLJungS. Lung macrophages serve as obligatory intermediate between blood monocytes and alveolar macrophages. J Immunol (2007) 179(6):3488–94. doi: 10.4049/jimmunol.179.6.3488

  • CrossRef
  • Google Scholar

• 202

  LandsmanLVarolCJungS. Distinct differentiation potential of blood monocyte subsets in the lung. J Immunol (2007) 178(4):2000–7. doi: 10.4049/jimmunol.178.4.2000

  • CrossRef
  • Google Scholar

• 203

  GeissmannFManzMGJungSSiewekeMHMeradMLeyK. Development of monocytes, macrophages, and dendritic cells. Science (2010) 327(5966):656–61. doi: 10.1126/science.1178331

  • CrossRef
  • Google Scholar

• 204

  FoggDKSibonCMiledCJungSAucouturierPLittmanDRet al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science (2006) 311(5757):83–7. doi: 10.1126/science.1117729

  • CrossRef
  • Google Scholar

• 205

  LiuKVictoraGDSchwickertTAGuermonprezPMeredithMMYaoKet al. In vivo analysis of dendritic cell development and homeostasis. Science (2009) 324(5925):392–7. doi: 10.1126/science.1170540

  • CrossRef
  • Google Scholar

• 206

  TrompetteAGollwitzerESPattaroniCLopez-MejiaICRivaEPernotJet al. Dietary fiber confers protection against flu by shaping Ly6c– patrolling monocyte hematopoiesis and CD8+ T cell metabolism. Immunity (2018) 48(5):992–1005.e8. doi: 10.1016/j.immuni.2018.04.022

  • CrossRef
  • Google Scholar

• 207

  LabonteACTosello-TrampontA-CHahnYS. The role of macrophage polarization in infectious and inflammatory diseases. Mol Cells (2014) 37(4):275. doi: 10.14348/molcells.2014.2374

  • CrossRef
  • Google Scholar

• 208

  ShireyKAPletnevaLMPucheACKeeganADPrinceGABlancoJCet al. Control of RSV-induced lung injury by alternatively activated macrophages is IL-4Rα-, TLR4-, and IFN-β-dependent. Mucosal Immunol (2010) 3(3):291–300. doi: 10.1038/mi.2010.6

  • CrossRef
  • Google Scholar

• 209

  YazarAAtisSKoncaKPataCAkbayECalikogluMet al. Respiratory symptoms and pulmonary functional changes in patients with irritable bowel syndrome. Am J gastroenterol (2001) 96(5):1511–6. doi: 10.1111/j.1572-0241.2001.03748.x

  • CrossRef
  • Google Scholar

• 210

  KeelySTalleyNJHansbroPM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol (2012) 5(1):7–18. doi: 10.1038/mi.2011.55

  • CrossRef
  • Google Scholar

• 211

  RuttenEPLenaertsKBuurmanWAWoutersEF. Disturbed intestinal integrity in patients with COPD: effects of activities of daily living. Chest (2014) 145(2):245–52. doi: 10.1378/chest.13-0584

  • CrossRef
  • Google Scholar

• 212

  DaiZ-LWuGZhuW-Y. Amino acid metabolism in intestinal bacteria: links between gut ecology and host health. Front Biosci-Landmark (2011) 16(5):1768–86. doi: 10.2741/3820

  • CrossRef
  • Google Scholar

• 213

  ZelanteTIannittiRGCunhaCDe LucaAGiovanniniGPieracciniGet al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity (2013) 39(2):372–85. doi: 10.1016/j.immuni.2013.08.003

  • CrossRef
  • Google Scholar

• 214

  VinoloMARodriguesHGHatanakaESatoFTSampaioSCCuriR. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem (2011) 22(9):849–55. doi: 10.1016/j.jnutbio.2010.07.009

  • CrossRef
  • Google Scholar

• 215

  UsamiMKishimotoKOhataAMiyoshiMAoyamaMFuedaYet al. Butyrate and trichostatin a attenuate nuclear factor κB activation and tumor necrosis factor α secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res (2008) 28(5):321–8. doi: 10.1016/j.nutres.2008.02.012

  • CrossRef
  • Google Scholar

• 216

  VenkateshMMukherjeeSWangHLiHSunKBenechetAPet al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and toll-like receptor 4. Immunity (2014) 41(2):296–310. doi: 10.1016/j.immuni.2014.06.014

  • CrossRef
  • Google Scholar

• 217

  MillerCA. Expression of the human aryl hydrocarbon receptor complex in yeast: activation of transcription by indole compounds. J Biol Chem (1997) 272(52):32824–9. doi: 10.1074/jbc.272.52.32824

  • CrossRef
  • Google Scholar

• 218

  QiuJHellerJJGuoXZong-mingECFishKFuY-Xet al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity (2012) 36(1):92–104. doi: 10.1016/j.immuni.2011.11.011

  • CrossRef
  • Google Scholar

• 219

  KawamataYFujiiRHosoyaMHaradaMYoshidaHMiwaMet al. AG protein-coupled receptor responsive to bile acids. J Biol Chem (2003) 278(11):9435–40. doi: 10.1074/jbc.M209706200

  • CrossRef
  • Google Scholar

• 220

  MaruyamaTMiyamotoYNakamuraTTamaiYOkadaHSugiyamaEet al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun (2002) 298(5):714–9. doi: 10.1016/S0006-291X(02)02550-0

  • CrossRef
  • Google Scholar

• 221

  ZhangZLiJZhengWZhaoGZhangHWangXet al. Peripheral lymphoid volume expansion and maintenance are controlled by gut microbiota via RALDH+ dendritic cells. Immunity (2016) 44(2):330–42. doi: 10.1016/j.immuni.2016.01.004

  • CrossRef
  • Google Scholar

• 222

  KissEAVonarbourgCKopfmannSHobeikaEFinkeDEsserCet al. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science (2011) 334(6062):1561–5. doi: 10.1126/science.1214914

  • CrossRef
  • Google Scholar

• 223

  LiYInnocentinSWithersDRRobertsNAGallagherARGrigorievaEFet al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell (2011) 147(3):629–40. doi: 10.1016/j.cell.2011.09.025

  • CrossRef
  • Google Scholar

• 224

  LeeJSCellaMMcDonaldKGGarlandaCKennedyGDNukayaMet al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of notch. Nat Immunol (2012) 13(2):144–51. doi: 10.1038/ni.2187

  • CrossRef
  • Google Scholar

• 225

  MadapoosiSSCruickshank-QuinnCOpronKErb-DownwardJRBegleyLALiGet al. Lung microbiota and metabolites collectively associate with clinical outcomes in milder stage chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2022) 206(4):427–39. doi: 10.1164/rccm.202110-2241OC

  • CrossRef
  • Google Scholar

• 226

  MarslandBJTrompetteAGollwitzerES. The gut–lung axis in respiratory disease. Ann Am Thorac Soc (2015) 12(Supplement 2):S150–S6. doi: 10.1513/AnnalsATS.201503-133AW

  • CrossRef
  • Google Scholar

• 227

  BuddenKFGellatlySLWoodDLCooperMAMorrisonMHugenholtzPet al. Emerging pathogenic links between microbiota and the gut–lung axis. Nat Rev Microbiol (2017) 15(1):55–63. doi: 10.1038/nrmicro.2016.142

  • CrossRef
  • Google Scholar

• 228

  EnaudRPrevelRCiarloEBeaufilsFWieërsGGueryBet al. The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks. Front Cell Infect Microbiol (2020) 10:9. doi: 10.3389/fcimb.2020.00009

  • CrossRef
  • Google Scholar

• 229

  DumasABernardLPoquetYLugo-VillarinoGNeyrollesO. The role of the lung microbiota and the gut–lung axis in respiratory infectious diseases. Cell Microbiol (2018) 20(12):e12966. doi: 10.1111/cmi.12966

  • CrossRef
  • Google Scholar

• 230

  BradleyCPTengFFelixKMSanoTNaskarDBlockKEet al. Segmented filamentous bacteria provoke lung autoimmunity by inducing gut-lung axis Th17 cells expressing dual TCRs. Cell Host Microbe (2017) 22(5):697–704.e4. doi: 10.1016/j.chom.2017.10.007

  • CrossRef
  • Google Scholar

• 231

  VaughanAFrazerZAHansbroPMYangIA. COPD and the gut-lung axis: the therapeutic potential of fibre. J Thorac dis (2019) 11(Suppl 17):S2173. doi: 10.21037/jtd.2019.10.40

  • CrossRef
  • Google Scholar

• 232

  HeYWenQYaoFXuDHuangYWangJ. Gut–lung axis: the microbial contributions and clinical implications. Crit Rev Microbiol (2017) 43(1):81–95. doi: 10.1080/1040841X.2016.1176988

  • CrossRef
  • Google Scholar

• 233

  BaccalaRGonzalez-QuintialRLawsonBRSternMEKonoDHBeutlerBet al. Sensors of the innate immune system: their mode of action. Nat Rev Rheumatol (2009) 5(8):448–56. doi: 10.1038/nrrheum.2009.136

  • CrossRef
  • Google Scholar

• 234

  SandorFBucM. Toll-like receptors. i. structure, function and their ligands. Folia biol (2005) 51(5):148.

  • Google Scholar

• 235

  CookDNPisetskyDSSchwartzDA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol (2004) 5(10):975–9. doi: 10.1038/ni1116

  • CrossRef
  • Google Scholar

• 236

  NguyenLTHaneyEFVogelHJ. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol (2011) 29(9):464–72. doi: 10.1016/j.tibtech.2011.05.001

  • CrossRef
  • Google Scholar

• 237

  CaballeroSKimSCarterRALeinerIMSušacBMillerLet al. Cooperating commensals restore colonization resistance to vancomycin-resistant enterococcus faecium. Cell Host Microbe (2017) 21(5):592–602.e4. doi: 10.1016/j.chom.2017.04.002

  • CrossRef
  • Google Scholar

• 238

  PapatriantafyllouM. Inflammasome shapes the microbiota. Nat Rev Immunol (2011) 11(7):439. doi: 10.1038/nri3012

  • CrossRef
  • Google Scholar

• 239

  HaraHSereginSSYangDFukaseKChamaillardMAlnemriESet al. The NLRP6 inflammasome recognizes lipoteichoic acid and regulates gram-positive pathogen infection. Cell (2018) 175(6):1651–64.e14. doi: 10.1016/j.cell.2018.09.047

  • CrossRef
  • Google Scholar

• 240

  GonçalvesPDi SantoJP. An intestinal inflammasome–the ILC3–cytokine tango. Trends Mol Med (2016) 22(4):269–71. doi: 10.1016/j.molmed.2016.02.008

  • CrossRef
  • Google Scholar

• 241

  ErttmannSFSwachaPAungKMBrindefalkBJiangHHärtlovaAet al. The gut microbiota prime systemic antiviral immunity via the cGAS-STING-IFN-I axis. Immunity (2022) 55(5):847–61.e10. doi: 10.1016/j.immuni.2022.04.006

  • CrossRef
  • Google Scholar

• 242

  KunisawaJNochiTKiyonoH. Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol (2008) 29(11):505–13. doi: 10.1016/j.it.2008.07.008

  • CrossRef
  • Google Scholar

• 243

  EvansSEScottBLClementCGLarsonDTKontoyiannisDLewisREet al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol (2010) 42(1):40–50. doi: 10.1165/rcmb.2008-0260OC

  • CrossRef
  • Google Scholar

• 244

  ReadRCWilsonRRutmanALundVToddHCBrainAPet al. Interaction of nontypable haemophilus influenzae with human respiratory mucosa in vitro. J Infect Dis (1991) 163(3):549–58. doi: 10.1093/infdis/163.3.549

  • CrossRef
  • Google Scholar

• 245

  GumJ. Mucin genes and the proteins they encode: structure, diversity, and regulation. Am J Respir Cell Mol Biol (1992) 7:557. doi: 10.1165/ajrcmb/7.6.557

  • CrossRef
  • Google Scholar

• 246

  ThaiPLoukoianovAWachiSWuR. Regulation of airway mucin gene expression. Annu Rev Physiol (2008) 70:405. doi: 10.1146/annurev.physiol.70.113006.100441

  • CrossRef
  • Google Scholar

• 247

  BergeronCBouletL-P. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest (2006) 129(4):1068–87. doi: 10.1378/chest.129.4.1068

  • CrossRef
  • Google Scholar

• 248

  RoseMCVoynowJA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev (2006) 86(1):245–78. doi: 10.1152/physrev.00010.2005

  • CrossRef
  • Google Scholar

• 249

  ThorntonDJGrayTNettesheimPHowardMKooJSSheehanJK. Characterization of mucins from cultured normal human tracheobronchial epithelial cells. Am J physiol-Lung Cell Mol Physiol (2000) 278(6):L1118–L28. doi: 10.1152/ajplung.2000.278.6.L1118

  • CrossRef
  • Google Scholar

• 250

  RousseauKByrneCKimYSGumJRSwallowDMToribaraNW. The complete genomic organization of the human MUC6 and MUC2 mucin genes. Genomics (2004) 83(5):936–9. doi: 10.1016/j.ygeno.2003.11.003

  • CrossRef
  • Google Scholar

• 251

  LiJ-DFengWGallupMKimJ-HGumJKimYet al. Activation of NF-κB via a src-dependent ras-MAPK-pp90rsk pathway is required for pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc Natl Acad Sci (1998) 95(10):5718–23. doi: 10.1073/pnas.95.10.5718

  • CrossRef
  • Google Scholar

• 252

  LiJDFengWGallupMKimJHGumJKimYet al. Activation of NF-kappaB via a src-dependent ras-MAPK-pp90rsk pathway is required for pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc Natl Acad Sci U S A. (1998) 95(10):5718–23. doi: 10.1073/pnas.95.10.5718

  • CrossRef
  • Google Scholar

• 253

  LemjabbarHBasbaumC. Platelet-activating factor receptor and ADAM10 mediate responses to staphylococcus aureus in epithelial cells. Nat Med (2002) 8(1):41–6. doi: 10.1038/nm0102-41

  • CrossRef
  • Google Scholar

• 254

  WrzosekLMiquelSNoordineM-LBouetSChevalier-CurtMJRobertVet al. Bacteroides thetaiotaomicron and faecalibacterium prausnitziiinfluence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol (2013) 11(1):1–13. doi: 10.1186/1741-7007-11-61

  • CrossRef
  • Google Scholar

• 255

  KellyCJZhengLCampbellELSaeediBScholzCCBaylessAJet al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe (2015) 17(5):662–71. doi: 10.1016/j.chom.2015.03.005

  • CrossRef
  • Google Scholar

• 256

  ZhengLKellyCJBattistaKDSchaeferRLanisJMAlexeevEEet al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor–dependent repression of claudin-2. J Immunol (2017) 199(8):2976–84. doi: 10.4049/jimmunol.1700105

  • CrossRef
  • Google Scholar

• 257

  RamosFLKrahnkeJSKimV. Clinical issues of mucus accumulation in COPD. Int J chronic obstructive pulm dis (2014) 9:139. doi: 10.2147/COPD.S38938

  • CrossRef
  • Google Scholar

• 258

  BurgelPMartinC. Mucus hypersecretion in COPD: should we only rely on symptoms? Eur Respir Rev (2010) 19(116):94–6. doi: 10.1183/09059180.00004410

  • CrossRef
  • Google Scholar

• 259

  KimVHanMKVanceGBMakeBJNewellJDHokansonJEet al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest (2011) 140(3):626–33. doi: 10.1378/chest.10-2948

  • CrossRef
  • Google Scholar

• 260

  AdlerKBHendleyDDDavisGS. Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways. Am J pathol (1986) 125(3):501.

  • Google Scholar

• 261

  LeikaufGDBorchersMTProwsDRSimpsonLG. Mucin apoprotein expression in COPD. Chest (2002) 121(5):166S–82S. doi: 10.1378/chest.121.5_suppl.166S

  • CrossRef
  • Google Scholar

• 262

  TurnerJJonesCE. Regulation of mucin expression in respiratory diseases. Biochem Soc Trans (2009) 37(4):877–81. doi: 10.1042/BST0370877

  • CrossRef
  • Google Scholar

• 263

  CaramoriGDi GregorioCCarlstedtICasolariPGuzzinatiIAdcockIet al. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology (2004) 45(5):477–84. doi: 10.1111/j.1365-2559.2004.01952.x

  • CrossRef
  • Google Scholar

• 264

  LuWZhengJ. The function of mucins in the COPD airway. Curr Respir Care Rep (2013) 2(3):155–66. doi: 10.1007/s13665-013-0051-3

  • CrossRef
  • Google Scholar

• 265

  CaramoriGCasolariPDi GregorioCSaettaMBaraldoSBoschettoPet al. MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. Histopathology (2009) 55(3):321–31. doi: 10.1111/j.1365-2559.2009.03377.x

  • CrossRef
  • Google Scholar

• 266

  Lo BelloFIeniAHansbroPMRuggeriPDi StefanoANuceraFet al. Role of the mucins in pathogenesis of COPD: implications for therapy. Expert Rev Respir Med (2020) 14(5):465–83. doi: 10.1080/17476348.2020.1739525

  • CrossRef
  • Google Scholar

• 267

  MaJRubinBKVoynowJA. Mucins, mucus, and goblet cells. Chest (2018) 154(1):169–76. doi: 10.1016/j.chest.2017.11.008

  • CrossRef
  • Google Scholar

• 268

  ZhengZQiYXuXJiangHLiZYangQet al. Sputum mucin 1 is increased during the acute phase of chronic obstructive pulmonary disease exacerbation. J Thorac dis (2017) 9(7):1873. doi: 10.21037/jtd.2017.06.63

  • CrossRef
  • Google Scholar

• 269

  VoynowJAGendlerSJRoseMC. Regulation of mucin genes in chronic inflammatory airway diseases. Am J Respir Cell Mol Biol (2006) 34(6):661–5. doi: 10.1165/rcmb.2006-0035SF

  • CrossRef
  • Google Scholar

• 270

  RadicioniGCeppeAFordAAAlexisNEBarrRGBleeckerERet al. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med (2021) 9(11):1241–54. doi: 10.1016/S2213-2600(21)00079-5

  • CrossRef
  • Google Scholar

• 271

  LangePNyboeJAppleyardMJensenGSchnohrP. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax (1990) 45(8):579–85. doi: 10.1136/thx.45.8.579

  • CrossRef
  • Google Scholar

• 272

  RogersDF. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther (2005) 18(1):1–8. doi: 10.1016/j.pupt.2004.08.001

  • CrossRef
  • Google Scholar

• 273

  ItoJTRamosDLimaFFRodriguesFMGomesPRMoreiraGLet al. Nasal mucociliary clearance in subjects with COPD after smoking cessation. Respir Care (2015) 60(3):399–405. doi: 10.4187/respcare.03266

  • CrossRef
  • Google Scholar

• 274

  BennettWDHendersonAGCeppeAZemanKLWuJGladmanCet al. Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis. ERJ Open Res (2020) 6(3). doi: 10.1183/23120541.00269-2020

  • CrossRef
  • Google Scholar

• 275

  SmaldoneGCFosterWMO'RiordanTGMessinaMSPerryRJLangenbackEG. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest (1993) 103(5):1390–6. doi: 10.1378/chest.103.5.1390

  • CrossRef
  • Google Scholar

• 276

  BhowmikAChahalKAustinGChakravortyI. Improving mucociliary clearance in chronic obstructive pulmonary disease. Respir Med (2009) 103(4):496–502. doi: 10.1016/j.rmed.2008.10.014

  • CrossRef
  • Google Scholar

• 277

  NawrothJCvan der DoesAMRyanAKansoE. Multiscale mechanics of mucociliary clearance in the lung. Philos Trans R Soc B (2020) 375(1792):20190160. doi: 10.1098/rstb.2019.0160

  • CrossRef
  • Google Scholar

• 278

  WhitsettJA. Airway epithelial differentiation and mucociliary clearance. Ann Am Thorac Soc (2018) 15(Supplement 3):S143–S8. doi: 10.1513/AnnalsATS.201802-128AW

  • CrossRef
  • Google Scholar

• 279

  HancockREHaneyEFGillEE. The immunology of host defence peptides: beyond antimicrobial activity. Nat Rev Immunol (2016) 16(5):321–34. doi: 10.1038/nri.2016.29

  • CrossRef
  • Google Scholar

• 280

  HancockRESahlH-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol (2006) 24(12):1551–7. doi: 10.1038/nbt1267

  • CrossRef
  • Google Scholar

• 281

  FjellCDHissJAHancockRESchneiderG. Designing antimicrobial peptides: form follows function. Nat Rev Drug disc (2012) 11(1):37–51. doi: 10.1038/nrd3591

  • CrossRef
  • Google Scholar

• 282

  BrogdenKA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol (2005) 3(3):238–50. doi: 10.1038/nrmicro1098

  • CrossRef
  • Google Scholar

• 283

  GanzT. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol (2003) 3(9):710–20. doi: 10.1038/nri1180

  • CrossRef
  • Google Scholar

• 284

  FabisiakAMurawskaNFichnaJ. LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity. Pharmacol Rep (2016) 68(4):802–8. doi: 10.1016/j.pharep.2016.03.015

  • CrossRef
  • Google Scholar

• 285

  SunEBelangerCRHaneyEFHancockRE. Host defense (antimicrobial) peptides. Pept Appl biomed Biotechnol bioeng (2018), 253–85. doi: 10.1016/B978-0-08-100736-5.00010-7

  • CrossRef
  • Google Scholar

• 286

  ZhangYJiangYSunCWangQYangZPanXet al. The human cathelicidin LL-37 enhances airway mucus production in chronic obstructive pulmonary disease. Biochem Biophys Res Commun (2014) 443(1):103–9. doi: 10.1016/j.bbrc.2013.11.074

  • CrossRef
  • Google Scholar

• 287

  ZuyderduynSNinaberDKHiemstraPSRabeKF. The antimicrobial peptide LL-37 enhances IL-8 release by human airway smooth muscle cells. J Allergy Clin Immunol (2006) 117(6):1328–35. doi: 10.1016/j.jaci.2006.03.022

  • CrossRef
  • Google Scholar

• 288

  CantorJOShteyngartBCerretaJMTurinoGM. The effect of lysozyme on elastase-mediated injury. Exp Biol Med (2002) 227(2):108–13. doi: 10.1177/153537020222700205

  • CrossRef
  • Google Scholar

• 289

  ParameswaranGISethiSMurphyTF. Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD. Chest (2011) 140(3):611–7. doi: 10.1378/chest.10-2760

  • CrossRef
  • Google Scholar

• 290

  OhbayashiHSetoguchiYFukuchiYShibataKSakataYAraiT. Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study. Eur Respir J (2014) 44(Suppl 58).

  • Google Scholar

• 291

  CohenABChenowethDEHugliTE. The release of elastase, myeloperoxidase, and lysozyme from human alveolar macrophages. Am Rev Respir Dis (1982) 126(2):241–7.

  • Google Scholar

• 292

  ParameswaranGSethiSMurphyT. Antimicrobial polypeptides and moraxella catarrhalis in COPD. B50 LUNG HOST DEFENSES TO INFECTION AND HOST CELL PATHOGEN INTERACTION. Am Thorac Soc (2009), A3225. doi: 10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A3225

  • CrossRef
  • Google Scholar

• 293

  RytiläPRehnTIlumetsHRouhosASovijärviAMyllärniemiMet al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res (2006) 7(1):1–10. doi: 10.1186/1465-9921-7-69

  • CrossRef
  • Google Scholar

• 294

  CulpittSVde MatosCRussellREDonnellyLERogersDFBarnesPJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 165(10):1371–6. doi: 10.1164/rccm.2105106

  • CrossRef
  • Google Scholar

• 295

  GompertzSBayleyDHillSStockleyR. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax (2001) 56(1):36–41. doi: 10.1136/thorax.56.1.36

  • CrossRef
  • Google Scholar

• 296

  PerssonLJAanerudMHardieJANilsenRMBakkePSEaganTMet al. Antimicrobial peptide levels are linked to airway inflammation, bacterial colonisation and exacerbations in chronic obstructive pulmonary disease. Eur Respir J (2017) 49(3). doi: 10.1183/13993003.01328-2016

  • CrossRef
  • Google Scholar

• 297

  CaneJTregidgoLThulbornSFinchDBafadhelM. Antimicrobial peptides SLPI and beta defensin-1 in sputum are negatively correlated with FEV1. Int J Chronic Obstructive Pulm Dis (2021) 16:1437. doi: 10.2147/COPD.S301622

  • CrossRef
  • Google Scholar

• 298

  TaggartCCLoweGJGreeneCMMulgrewATO'NeillSJLevineRLet al. Cathepsin b, l, and s cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem (2001) 276(36):33345–52. doi: 10.1074/jbc.M103220200

  • CrossRef
  • Google Scholar

• 299

  ZhengTZhuZWangZHomerRJMaBRieseRJet al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase–and cathepsin-dependent emphysema. J Clin Invest (2000) 106(9):1081–93. doi: 10.1172/JCI10458

  • CrossRef
  • Google Scholar

• 300

  ZhengTKangMJCrothersKZhuZLiuWLeeCGet al. Role of cathepsin s-dependent epithelial cell apoptosis in IFN-γ-induced alveolar remodeling and pulmonary emphysema. J Immunol (2005) 174(12):8106–15. doi: 10.4049/jimmunol.174.12.8106

  • CrossRef
  • Google Scholar

• 301

  BarnesPJShapiroSDPauwelsR. Chronic obstructive pulmonary disease: molecular and cellularmechanisms. Eur Respir J (2003) 22(4):672–88. doi: 10.1183/09031936.03.00040703

  • CrossRef
  • Google Scholar

• 302

  NakajimaTNakamuraHOwenCAYoshidaSTsudukiKChubachiSet al. Plasma cathepsin s and cathepsin s/cystatin c ratios are potential biomarkers for COPD. Dis Markers (2016) 2016. doi: 10.1155/2016/4093870

  • CrossRef
  • Google Scholar

• 303

  AndraultP-MSchambergerACChazeiratTSizaretDRenaultJStaab-WeijnitzCAet al. Cigarette smoke induces overexpression of active human cathepsin s in lungs from current smokers with or without COPD. Am J Physiol-Lung Cell Mol Physiol (2019) 317(5):L625–L38. doi: 10.1152/ajplung.00061.2019

  • CrossRef
  • Google Scholar

• 304

  NganDAVickermanSVGranvilleDJManSPSinDD. The possible role of granzyme b in the pathogenesis of chronic obstructive pulmonary disease. Ther Adv Respir Dis (2009) 3(3):113–29. doi: 10.1177/1753465809341965

  • CrossRef
  • Google Scholar

• 305

  HodgeSHodgeGNairnJHolmesMReynoldsPN. Increased airway granzyme b and perforin in current and ex-smoking COPD subjects. COPD: J Chronic Obstructive Pulm Dis (2006) 3(4):179–87. doi: 10.1080/15412550600976868

  • CrossRef
  • Google Scholar

• 306

  VernooyJHMoüllerGMvan SuylenRJvan SpijkMPClootsRHHoetPHet al. Increased granzyme a expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 175(5):464–72. doi: 10.1164/rccm.200602-169OC

  • CrossRef
  • Google Scholar

• 307

  GolecMReichelCMackiewiczBSkórskaCCurzytekKLemieszekMet al. Cathelicidin LL-37, granzymes, TGF-beta1 and cytokines levels in induced sputum from farmers with and without COPD. Ann Agric Environ Med (2009) 16(2):289–97.

  • Google Scholar

• 308

  MorissetteMCParentJMilotJ. Perforin, granzyme b, and FasL expression by peripheral blood T lymphocytes in emphysema. Respir Res (2007) 8(1):1–9. doi: 10.1186/1465-9921-8-62

  • CrossRef
  • Google Scholar

• 309

  KimWDChiHSChoeKHOhYMLeeSDKimKRet al. A possible role for CD 8+ and non-CD 8+ cell granzyme b in early small airway wall remodelling in centrilobular emphysema. Respirology (2013) 18(4):688–96. doi: 10.1111/resp.12069

  • CrossRef
  • Google Scholar

• 310

  SattarZLoraAJundiBRailwahCGeraghtyP. The S100 protein family as players and therapeutic targets in pulmonary diseases. Pulm Med (2021) 2021. doi: 10.1155/2021/5488591

  • CrossRef
  • Google Scholar

• 311

  LinC-RBahmedKCrinerGJMarchettiNTuderRMKelsenSet al. S100A8 protects human primary alveolar type II cells against injury and emphysema. Am J Respir Cell Mol Biol (2019) 60(3):299–307. doi: 10.1165/rcmb.2018-0144OC

  • CrossRef
  • Google Scholar

• 312

  KimRYSunkaraKPBrackeKRJarnickiAGDonovanCHsuACet al. A microRNA-21–mediated SATB1/S100A9/NF-κB axis promotes chronic obstructive pulmonary disease pathogenesis. Sci Trans Med (2021) 13(621):eaav7223. doi: 10.1126/scitranslmed.aav7223

  • CrossRef
  • Google Scholar

• 313

  LorenzEMuhlebachMSTessierPAAlexisNEHiteRDSeedsMCet al. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med (2008) 102(4):567–73. doi: 10.1016/j.rmed.2007.11.011

  • CrossRef
  • Google Scholar

• 314

  RailwahCLoraAZahidKGoldenbergHCamposMWymanAet al. Cigarette smoke induction of S100A9 contributes to chronic obstructive pulmonary disease. Am J Physiol-Lung Cell Mol Physiol (2020) 319(6):L1021–L35. doi: 10.1152/ajplung.00207.2020

  • CrossRef
  • Google Scholar

• 315

  PouwelsSDHeijinkIHten HackenNHVandenabeelePKryskoDVNawijnMCet al. DAMPs activating innate and adaptive immune responses in COPD. Mucosal Immunol (2014) 7(2):215–26. doi: 10.1038/mi.2013.77

  • CrossRef
  • Google Scholar

• 316

  Skronska-WasekWDurlanikSLeHQSchroederVKittKGarnettJPet al. The antimicrobial peptide S100A8/A9 produced by airway epithelium functions as a potent and direct regulator of macrophage phenotype and function. Eur Respir J (2022) 59(4). doi: 10.1183/13993003.02732-2020

  • CrossRef
  • Google Scholar

• 317

  AndresenELangeCStrodthoffDGoldmannTFischerNSahlyHet al. S100A7/psoriasin expression in the human lung: unchanged in patients with COPD, but upregulated upon positive s. aureusdetection. BMC pulm Med (2011) 11(1):1–10. doi: 10.1186/1471-2466-11-10

  • CrossRef
  • Google Scholar

• 318

  VandammeDLanduytBLuytenWSchoofsL. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol (2012) 280(1):22–35. doi: 10.1016/j.cellimm.2012.11.009

  • CrossRef
  • Google Scholar

• 319

  NijnikAHancockRE. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin hematol (2009) 16(1):41–7. doi: 10.1097/MOH.0b013e32831ac517

  • CrossRef
  • Google Scholar

• 320

  XhindoliDPacorSBenincasaMScocchiMGennaroRTossiA. The human cathelicidin LL-37–a pore-forming antibacterial peptide and host-cell modulator. Biochim Biophys Acta (BBA)-Biomem (2016) 1858(3):546–66. doi: 10.1016/j.bbamem.2015.11.003

  • CrossRef
  • Google Scholar

• 321

  SchneiderVACoorensMOrdonezSRTjeerdsma-van BokhovenJLPosthumaGvan DijkAet al. Imaging the antimicrobial mechanism (s) of cathelicidin-2. Sci Rep (2016) 6(1):1–11. doi: 10.1038/srep32948

  • CrossRef
  • Google Scholar

• 322

  RamanathanBDavisEGRossCRBlechaF. Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. Microbes infec (2002) 4(3):361–72. doi: 10.1016/S1286-4579(02)01549-6

  • CrossRef
  • Google Scholar

• 323

  YuJMookherjeeNWeeKBowdishDMPistolicJLiYet al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1β, augments immune responses by multiple pathways. J Immunol (2007) 179(11):7684–91. doi: 10.4049/jimmunol.179.11.7684

  • CrossRef
  • Google Scholar

• 324

  PericMKoglinSKimS-MMorizaneSBeschRPrinzJCet al. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol (2008) 181(12):8504–12. doi: 10.4049/jimmunol.181.12.8504

  • CrossRef
  • Google Scholar

• 325

  MinnsDSmithKJAlessandriniVHardistyGMelroseLJackson-JonesLet al. The neutrophil antimicrobial peptide cathelicidin promotes Th17 differentiation. Nat Commun (2021) 12(1):1–16. doi: 10.1038/s41467-021-21533-5

  • CrossRef
  • Google Scholar

• 326

  MookherjeeNHamillPGardyJBlimkieDFalsafiRChikatamarlaAet al. Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. Mol BioSyst (2009) 5(5):483–96. doi: 10.1039/b813787k

  • CrossRef
  • Google Scholar

• 327

  ShaykhievRSierigkJHerrCKrastevaGKummerWBalsR. The antimicrobial peptide cathelicidin enhances activation of lung epithelial cells by LPS. FASEB J (2010) 24(12):4756–66. doi: 10.1096/fj.09.151332

  • CrossRef
  • Google Scholar

• 328

  KandlerKShaykhievRKleemannPKlesczFLohoffMVogelmeierCet al. The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands. Int Immunol (2006) 18(12):1729–36. doi: 10.1093/intimm/dxl107

  • CrossRef
  • Google Scholar

• 329

  KhooA-LChaiLYKoenenHJOostingMSteinmeyerAZuegelUet al. Vitamin D3 down-regulates proinflammatory cytokine response to mycobacterium tuberculosis through pattern recognition receptors while inducing protective cathelicidin production. Cytokine (2011) 55(2):294–300. doi: 10.1016/j.cyto.2011.04.016

  • CrossRef
  • Google Scholar

• 330

  van der DoesAMBeekhuizenHRavensbergenBVosTOttenhoffTHvan DisselJTet al. LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J Immunol (2010) 185(3):1442–9. doi: 10.4049/jimmunol.1000376

  • CrossRef
  • Google Scholar

• 331

  DavidsonDJCurrieAJReidGSBowdishDMMacDonaldKLMaRCet al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol (2004) 172(2):1146–56. doi: 10.4049/jimmunol.172.2.1146

  • CrossRef
  • Google Scholar

• 332

  ElssnerADuncanMGavrilinMWewersMD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1β processing and release. J Immunol (2004) 172(8):4987–94. doi: 10.4049/jimmunol.172.8.4987

  • CrossRef
  • Google Scholar

• 333

  WangT-TNestelFPBourdeauVNagaiYWangQLiaoJet al. Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol (2004) 173(5):2909–12. doi: 10.4049/jimmunol.173.5.2909

  • CrossRef
  • Google Scholar

• 334

  HilchieALWuerthKHancockRE. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol (2013) 9(12):761–8. doi: 10.1038/nchembio.1393

  • CrossRef
  • Google Scholar

• 335

  PeyssonnauxCBoutinATZinkernagelASDattaVNizetVJohnsonRS. Critical role of HIF-1α in keratinocyte defense against bacterial infection. J Invest Dermatol (2008) 128(8):1964–8. doi: 10.1038/jid.2008.27

  • CrossRef
  • Google Scholar

• 336

  KnudsenKSLehmannSNielsenRTangedalSHaalandIHiemstraPSet al. The lower airways microbiome and antimicrobial peptides in idiopathic pulmonary fibrosis differ from chronic obstructive pulmonary disease. PloS One (2022) 17(1):e0262082. doi: 10.1371/journal.pone.0262082

  • CrossRef
  • Google Scholar

• 337

  CaneJThulbornSPiperSFinchDBafadhelM. Antimicrobial peptides in inflammatory phenotypes of COPD. Thorax (2017). doi: 10.1136/thoraxjnl-2017-210983.255

  • CrossRef
  • Google Scholar

• 338

  PerssonLAanerudMHardieJABakkePSEaganTMHiemstraPS. Associations between haemophilus influenzae and levels of sputum antimicrobial peptides in COPD. Eur Respir Soc (2016) 48(Suppl_2). doi: 10.1183/13993003.congress-2016.OA4994

  • CrossRef
  • Google Scholar

• 339

  SeilerFBalsRBeisswengerC. Function of antimicrobial peptides in lung innate immunity. Antimicrobial Peptides (2016), 33–52. doi: 10.1007/978-3-319-24199-9_3

  • CrossRef
  • Google Scholar

• 340

  NeumannABerendsETNerlichAMolhoekEMGalloRLMeerlooTet al. The antimicrobial peptide LL-37 facilitates the formation of neutrophil extracellular traps. Biochem J (2014) 464(1):3–11. doi: 10.1042/BJ20140778

  • CrossRef
  • Google Scholar

• 341

  TjabringaGSNinaberDKDrijfhoutJWRabeKFHiemstraPS. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int Arch Allergy Immunol (2006) 140(2):103–12. doi: 10.1159/000092305

  • CrossRef
  • Google Scholar

• 342

  van der DoesAMHiemstraPSMookherjeeN. Antimicrobial host defence peptides: immunomodulatory functions and translational prospects. Antimicrobial Peptides (2019), 149–71. doi: 10.1007/978-981-13-3588-4_10

  • CrossRef
  • Google Scholar

• 343

  HuangJT-JCantEKeirHRBartonAKKuzmanovaEShuttleworthMet al. Endotyping COPD, bronchiectasis and the ‘COPD-bronchiectasis association’. Am J Respir Crit Care Med (2022) 206(4). doi: 10.1164/rccm.202108-1943OC

  • CrossRef
  • Google Scholar

• 344

  van WeteringSTjabringaGSHiemstraPS. Interactions between neutrophil-derived antimicrobial peptides and airway epithelial cells. J leukoc Biol (2005) 77(4):444–50. doi: 10.1189/jlb.0604367

  • CrossRef
  • Google Scholar

• 345

  HerrCAlAlwaniSEschmannRBeißwengerCBalsR. The antimicrobial peptide CRAMP protects against emphysema. Eur Respir Soc; (2012) 40(56).

  • Google Scholar

• 346

  ZhuMWangTWangCJiY. The association between vitamin d and COPD risk, severity, and exacerbation: an updated systematic review and meta-analysis. Int J chronic obstructive pulm dis (2016) 11:2597. doi: 10.2147/COPD.S101382

  • CrossRef
  • Google Scholar

• 347

  SibilaOPereaLCantóEShoemarkACassidyDSmithAHet al. Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax (2019) 74(9):835–42. doi: 10.1136/thoraxjnl-2018-212895

  • CrossRef
  • Google Scholar

• 348

  BurkesRMCeppeASCouperDJComellasAPWellsJMPetersSPet al. Plasma cathelicidin is independently associated with reduced lung function in COPD: analysis of the subpopulations and intermediate outcome measures in COPD study cohort. Chronic Obstructive Pulm Dis: J COPD Found (2020) 7(4):370. doi: 10.15326/jcopdf.7.4.2020.0142

  • CrossRef
  • Google Scholar

• 349

  GolecMLemieszekMKDutkiewiczJMilanowskiJBarteitS. A scoping analysis of cathelicidin in response to organic dust exposure and related chronic lung illnesses. Int J Mol Sci (2022) 23(16):8847. doi: 10.3390/ijms23168847

  • CrossRef
  • Google Scholar

• 350

  LambertAAKirkGDAstemborskiJNeptuneERMehtaSHWiseRAet al. A cross sectional analysis of the role of the antimicrobial peptide cathelicidin in lung function impairment within the ALIVE cohort. PloS One (2014) 9(4):e95099. doi: 10.1371/journal.pone.0095099

  • CrossRef
  • Google Scholar

• 351

  BurkesRMAstemborskiJLambertAABrownTTWiseRAKirkGDet al. Plasma cathelicidin and longitudinal lung function in current and former smokers. PloS One (2019) 14(2):e0212628. doi: 10.1371/journal.pone.0212628

  • CrossRef
  • Google Scholar

• 352

  SinganayagamAGlanvilleNCuthbertsonLBartlettNWFinneyLJTurekEet al. Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary disease. Sci Trans Med (2019) 11(507):eaav3879. doi: 10.1126/scitranslmed.aav3879

  • CrossRef
  • Google Scholar

• 353

  AlalwaniMS. Cathelicidin has a protective role against pulmonary emphysema. Eur Respir J (2014) 44(Suppl 58).

  • Google Scholar

• 354

  GolecMReichelCLemieszekMMackiewiczBBuczkowskiJSitkowskaJet al. Cathelicidin LL-37 in bronchoalveolar lavage and epithelial lining fluids from COPD patients and healthy individuals. J Biol regulators homeostatic agents (2012) 26(4):617–25.

  • Google Scholar

• 355

  XiaoWHsuY-PIshizakaAKirikaeTMossRB. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest (2005) 128(4):2316–26. doi: 10.1378/chest.128.4.2316

  • CrossRef
  • Google Scholar

• 356

  KeirHRRichardsonHGilmourADe LimaDAVeluchamyAHennayakeCet al. The cathelicidin LL-37 and microbial dysbiosis in COPD patients receiving inhaled corticosteroids. Eur Respir Soc (2022) 8(8). doi: 10.1183/23120541.LSC-2022.185

  • CrossRef
  • Google Scholar

• 357

  BurkesRCeppeADonohueJDoerschukCDrummondM. Plasma cathelicidin measurements during COPD exacerbations and outcomes. C32 COPD: TRANSLATIONAL AND MECHANISTIC STUDIES. Am Thorac Soc (2019), A4530–A. doi: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A4530

  • CrossRef
  • Google Scholar

• 358

  AkirovA. Targeting chronic obstructive pulmonary disease endotypes. COPD (2021).

  • Google Scholar

• 359

  JiangY-YXiaoWZhuM-XYangZ-HPanX-JZhangYet al. The effect of human antibacterial peptide LL-37 in the pathogenesis of chronic obstructive pulmonary disease. Respir Med (2012) 106(12):1680–9. doi: 10.1016/j.rmed.2012.08.018

  • CrossRef
  • Google Scholar

• 360

  TatsutaMKan-oKIshiiYYamamotoNOgawaTFukuyamaSet al. Effects of cigarette smoke on barrier function and tight junction proteins in the bronchial epithelium: protective role of cathelicidin LL-37. Respir Res (2019) 20(1):1–14. doi: 10.1186/s12931-019-1226-4

  • CrossRef
  • Google Scholar

• 361

  YangY-MGuoY-FZhangH-SSunT-Y. Antimicrobial peptide LL-37 circulating levels in chronic obstructive pulmonary disease patients with high risk of frequent exacerbations. J Thorac dis (2015) 7(4):740. doi: 10.3978/j.issn.2072-1439.2015.04.33

  • CrossRef
  • Google Scholar

• 362

  LehouckAMathieuCCarremansCBaekeFVerhaegenJVan EldereJet al. High doses of vitamin d to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Internal Med (2012) 156(2):105–14. doi: 10.7326/0003-4819-156-2-201201170-00004

  • CrossRef
  • Google Scholar

• 363

  MathyssenCAelbrechtCSerréJEveraertsSMaesKGayan-RamirezGet al. Local expression profiles of vitamin d-related genes in airways of COPD patients. Respir Res (2020) 21(1):1–10. doi: 10.1186/s12931-020-01405-0

  • CrossRef
  • Google Scholar

• 364

  KokturkNBahaAOhYMYoung JuJJonesPW. Vitamin d deficiency: What does it mean for chronic obstructive pulmonary disease (COPD)? a compherensive review for pulmonologists. Clin Respir J (2018) 12(2):382–97. doi: 10.1111/crj.12588

  • CrossRef
  • Google Scholar

• 365

  SoerotoAYSetiawanDAsriputriNNDarmawanGLaurusGSantosoP. Association between vitamin d levels and FEV1, number of exacerbations, and CAT score in stable COPD patients in Indonesia. Int J Gen Med (2021) 14:7293. doi: 10.2147/IJGM.S333039

  • CrossRef
  • Google Scholar

• 366

  UysalPSimsekGDurmusSSÖZERVAksanHYurtSet al. Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease. Int J Chronic Obstructive Pulm Dis (2019) 14. doi: 10.2147/COPD.S185602

  • CrossRef
  • Google Scholar

• 367

  BurkesRCeppeAO'NealWHanMCurtisJComellasAet al. Low plasma cathelicidin levels are associated with reduced lung function and prior COPD exacerbations: An analysis of the SPIROMICS cohort. Am J Resp Med (AJRCCM) (2018) 197:A7442–A.

  • Google Scholar

• 368

  HazlettLWuM. Defensins in innate immunity. Cell Tissue Res (2011) 343(1):175–88. doi: 10.1007/s00441-010-1022-4

  • CrossRef
  • Google Scholar

• 369

  TangY-QSelstedM. Characterization of the disulfide motif in BNBD-12, an antimicrobial beta-defensin peptide from bovine neutrophils. J Biol Chem (1993) 268(9):6649–53. doi: 10.1016/S0021-9258(18)53299-3

  • CrossRef
  • Google Scholar

• 370

  SempleFDorinJR. β-defensins: multifunctional modulators of infection, inflammation and more? J innate Immun (2012) 4(4):337–48. doi: 10.1159/000336619

  • CrossRef
  • Google Scholar

• 371

  HarderJrBartelsJChristophersESchroüderJ-M. Isolation and characterization of human μ-Defensin-3, a novel human inducible peptide antibiotic. J Biol Chem (2001) 276(8):5707–13. doi: 10.1074/jbc.M008557200

  • CrossRef
  • Google Scholar

• 372

  GarcíaJ-RCKrauseASchulzSRodríguez-JiménezF-JKlüverEAdermannKet al. Human β-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J (2001) 15(10):1819–21. doi: 10.1096/fj.00-0865fje

  • CrossRef
  • Google Scholar

• 373

  SoehnleinOKai-LarsenYFrithiofRSorensenOEKenneEScharffetter-KochanekKet al. Neutrophil primary granule proteins HBP and HNP1–3 boost bacterial phagocytosis by human and murine macrophages. J Clin Invest (2008) 118(10):3491–502. doi: 10.1172/JCI35740

  • CrossRef
  • Google Scholar

• 374

  MilesKClarkeDJLuWSibinskaZBeaumontPEDavidsonDJet al. Dying and necrotic neutrophils are anti-inflammatory secondary to the release of α-defensins. J Immunol (2009) 183(3):2122–32. doi: 10.4049/jimmunol.0804187

  • CrossRef
  • Google Scholar

• 375

  HiemstraPVan WeteringSStolkJ. Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium. Eur Respir J (1998) 12(5):1200–8. doi: 10.1183/09031936.98.12051200

  • CrossRef
  • Google Scholar

• 376

  MatsushitaIHasegawaKNakataKYasudaKTokunagaKKeichoN. Genetic variants of human β-defensin-1 and chronic obstructive pulmonary disease. Biochem Biophys Res Commun (2002) 291(1):17–22. doi: 10.1006/bbrc.2002.6395

  • CrossRef
  • Google Scholar

• 377

  PaceEFerraroMMinerviniMIVituloPPipitoneLChiapparaGet al. Beta defensin-2 is reduced in central but not in distal airways of smoker COPD patients. PloS One (2012) 7(3):e33601. doi: 10.1371/journal.pone.0033601

  • CrossRef
  • Google Scholar

• 378

  AndresenEGüntherGBullwinkelJLangeCHeineH. Increased expression of beta-defensin 1 (DEFB1) in chronic obstructive pulmonary disease. PloS One (2011) 6(7):e21898. doi: 10.1371/journal.pone.0021898

  • CrossRef
  • Google Scholar

• 379

  LiaoZDongJHuXWangTWanCLiLet al. Enhanced expression of human β-defensin 2 in peripheral lungs of patients with chronic obstructive pulmonary disease. Peptides (2012) 38(2):350–6. doi: 10.1016/j.peptides.2012.09.013

  • CrossRef
  • Google Scholar

• 380

  WallaceAMHeJ-QBurkettKMRuanJConnettJEAnthonisenNRet al. Contribution of alpha-and beta-defensins to lung function decline and infection in smokers: an association study. Respir Res (2006) 7(1):1–8. doi: 10.1186/1465-9921-7-76

  • CrossRef
  • Google Scholar

• 381

  PiersonTLearmonth-PiersonSPintoDvan HoekML. Cigarette smoke extract induces differential expression levels of beta-defensin peptides in human alveolar epithelial cells. Tobacco induced dis (2013) 11(1):1–8. doi: 10.1186/1617-9625-11-10

  • CrossRef
  • Google Scholar

• 382

  SchutteBCMcCrayPBJr. (Beta)-defensins in lung host defense. Annu Rev Physiol (2002) 64:709. doi: 10.1146/annurev.physiol.64.081501.134340

  • CrossRef
  • Google Scholar

• 383

  ChenCI-USchaller-BalsSPaulKPWahnUBalsR. β-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J Cystic Fibrosis (2004) 3(1):45–50. doi: 10.1016/j.jcf.2003.12.008

  • CrossRef
  • Google Scholar

• 384

  HiratsukaTMukaeHIiboshiHAshitaniJNabeshimaKMinematsuTet al. Increased concentrations of human β-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax (2003) 58(5):425–30. doi: 10.1136/thorax.58.5.425

  • CrossRef
  • Google Scholar

• 385

  BdeirKHigaziAA-RKulikovskayaIChristofidou-SolomidouMVinogradovSAAllenTCet al. Neutrophil α-defensins cause lung injury by disrupting the capillary–epithelial barrier. Am J Respir Crit Care Med (2010) 181(9):935–46. doi: 10.1164/rccm.200907-1128OC

  • CrossRef
  • Google Scholar

• 386

  ChengMChenYWangLChenWYangLShenGet al. Commensal microbiota maintains alveolar macrophages with a low level of CCL24 production to generate anti-metastatic tumor activity. Sci Rep (2017) 7(1):1–12. doi: 10.1038/s41598-017-08264-8

  • CrossRef
  • Google Scholar

• 387

  BrownRLSequeiraRPClarkeTB. The microbiota protects against respiratory infection via GM-CSF signaling. Nat Commun (2017) 8(1):1–11. doi: 10.1038/s41467-017-01803-x

  • CrossRef
  • Google Scholar

• 388

  KhanNMendoncaLDhariwalAFontesGMenziesDXiaJet al. Intestinal dysbiosis compromises alveolar macrophage immunity to mycobacterium tuberculosis. Mucosal Immunol (2019) 12(3):772–83. doi: 10.1038/s41385-019-0147-3

  • CrossRef
  • Google Scholar

• 389

  SchuijtTJLankelmaJMSciclunaBPe MeloFRoelofsJJde BoerJDet al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut (2016) 65(4):575–83. doi: 10.1136/gutjnl-2015-309728

  • CrossRef
  • Google Scholar

• 390

  CohenSBGernBHDelahayeJLAdamsKNPlumleeCRWinklerJKet al. Alveolar macrophages provide an early mycobacterium tuberculosis niche and initiate dissemination. Cell Host Microbe (2018) 24(3):439–46.e4. doi: 10.1016/j.chom.2018.08.001

  • CrossRef
  • Google Scholar

• 391

  GutierrezPClosaDPiñerRBulbenaOMenéndezRTorresA. Macrophage activation in exacerbated COPD with and without community-acquired pneumonia. Eur Respir J (2010) 36(2):285–91. doi: 10.1183/09031936.00118909

  • CrossRef
  • Google Scholar

• 392

  ShaykhievRKrauseASalitJStrulovici-BarelYHarveyB-GO'ConnorTPet al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J Immunol (2009) 183(4):2867–83. doi: 10.4049/jimmunol.0900473

  • CrossRef
  • Google Scholar

• 393

  GharibSAManiconeAMParksWC. Matrix metalloproteinases in emphysema. Matrix Biol (2018) 73:34–51. doi: 10.1016/j.matbio.2018.01.018

  • CrossRef
  • Google Scholar

• 394

  ChurgAZhouSWrightJL. Matrix metalloproteinases in COPD. Eur Respir J (2012) 39(1):197–209. doi: 10.1183/09031936.00121611

  • CrossRef
  • Google Scholar

• 395

  TetleyTD. Macrophages and the pathogenesis of COPD. Chest (2002) 121(5):156S–9S. doi: 10.1378/chest.121.5_suppl.156S

  • CrossRef
  • Google Scholar

• 396

  BarnesPJ. New treatments for COPD. Nat Rev Drug disc (2002) 1(6):437–46. doi: 10.1038/nrd820

  • CrossRef
  • Google Scholar

• 397

  ZhangDFrenettePS. Cross talk between neutrophils and the microbiota. Blood J Am Soc Hematol (2019) 133(20):2168–77. doi: 10.1182/blood-2018-11-844555

  • CrossRef
  • Google Scholar

• 398

  ZhangDChenGManwaniDMorthaAXuCFaithJJet al. Neutrophil ageing is regulated by the microbiome. Nature (2015) 525(7570):528–32. doi: 10.1038/nature15367

  • CrossRef
  • Google Scholar

• 399

  FagundesCTAmaralFAVieiraATSoaresACPinhoVNicoliJRet al. Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice. J Immunol (2012) 188(3):1411–20. doi: 10.4049/jimmunol.1101682

  • CrossRef
  • Google Scholar

• 400

  KarmarkarDRockKL. Microbiota signalling through MyD88 is necessary for a systemic neutrophilic inflammatory response. Immunology (2013) 140(4):483–92. doi: 10.1111/imm.12159

  • CrossRef
  • Google Scholar

• 401

  Abi AbdallahDSEganCEButcherBADenkersEY. Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation. Int Immunol (2011) 23(5):317–26. doi: 10.1093/intimm/dxr007

  • CrossRef
  • Google Scholar

• 402

  DeshmukhHSLiuYMenkitiORMeiJDaiNO'learyCEet al. The microbiota regulates neutrophil homeostasis and host resistance to escherichia coli K1 sepsis in neonatal mice. Nat Med (2014) 20(5):524–30. doi: 10.1038/nm.3542

  • CrossRef
  • Google Scholar

• 403

  AmatngalimGDSchrumpfJAHenicADronkersEVerhooselRMOrdonezSRet al. Antibacterial defense of human airway epithelial cells from chronic obstructive pulmonary disease patients induced by acute exposure to nontypeable haemophilus influenzae: modulation by cigarette smoke. J innate immun (2017) 9(4):359–74. doi: 10.1159/000455193

  • CrossRef
  • Google Scholar

• 404

  GómezMIPrinceA. Airway epithelial cell signaling in response to bacterial pathogens. Pediatr pulmonol (2008) 43(1):11–9. doi: 10.1002/ppul.20735

  • CrossRef
  • Google Scholar

• 405

  LiuXYinSChenYWuYZhengWDongHet al. LPS−induced proinflammatory cytokine expression in human airway epithelial cells and macrophages via NF−κB, STAT3 or AP−1 activation. Mol Med Rep (2018) 17(4):5484–91. doi: 10.3892/mmr.2018.8542

  • CrossRef
  • Google Scholar

• 406

  BertelsenAElbornJSSchockBC. Microbial interaction: Prevotella spp. reduce p. aeruginosa induced inflammation in cystic fibrosis bronchial epithelial cells. J Cystic Fibrosis (2021) 20(4):682–91. doi: 10.1016/j.jcf.2021.04.012

  • CrossRef
  • Google Scholar

• 407

  ObermayerAStoiberWKrautgartnerW-DKlappacherMKoflerBSteinbacherPet al. New aspects on the structure of neutrophil extracellular traps from chronic obstructive pulmonary disease and in vitro generation. PloS One (2014) 9(5):e97784. doi: 10.1371/journal.pone.0097784

  • CrossRef
  • Google Scholar

• 408

  Grabcanovic-MusijaFObermayerAStoiberWKrautgartnerW-DSteinbacherPWinterbergNet al. Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitation. Respir Res (2015) 16(1):1–12. doi: 10.1186/s12931-015-0221-7

  • CrossRef
  • Google Scholar

• 409

  PedersenFWaschkiBMarwitzSGoldmannTKirstenAMalmgrenAet al. Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils. Eur Respir J (2018) 51(4). doi: 10.1183/13993003.00970-2017

  • CrossRef
  • Google Scholar

• 410

  PandeyKCDeSMishraPK. Role of proteases in chronic obstructive pulmonary disease. Front Pharmacol (2017) 8:512. doi: 10.3389/fphar.2017.00512

  • CrossRef
  • Google Scholar

• 411

  StockleyRA. Neutrophils and the pathogenesis of COPD. Chest (2002) 121(5):151S–5S. doi: 10.1378/chest.121.5_suppl.151S

  • CrossRef
  • Google Scholar

• 412

  ChurgAWrightJL. Proteases and emphysema. Curr Opin pulm Med (2005) 11(2):153–9. doi: 10.1097/01.mcp.0000149592.51761.e3

  • CrossRef
  • Google Scholar

• 413

  InuiTWatanabeMNakamotoKSadaMHirataANakamuraMet al. Bronchial epithelial cells produce CXCL1 in response to LPS and TNFα: A potential role in the pathogenesis of COPD. Exp Lung Res (2018) 44(7):323–31. doi: 10.1080/01902148.2018.1520936

  • CrossRef
  • Google Scholar

• 414

  BarnesPJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol (2008) 8(3):183–92. doi: 10.1038/nri2254

  • CrossRef
  • Google Scholar

• 415

  TravesSLDonnellyLE. Th17 cells in airway diseases. Curr Mol Med (2008) 8(5):416–26. doi: 10.2174/156652408785160998

  • CrossRef
  • Google Scholar

• 416

  SeoG-YGilesDAKronenbergM. The role of innate lymphoid cells in response to microbes at mucosal surfaces. Mucosal Immunol (2020) 13(3):399–412. doi: 10.1038/s41385-020-0265-y

  • CrossRef
  • Google Scholar

• 417

  SonnenbergGFMonticelliLAAlenghatTFungTCHutnickNAKunisawaJet al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 336(6086):1321–5. doi: 10.1126/science.1222551

  • CrossRef
  • Google Scholar

• 418

  Gury-BenAriMThaissCASerafiniNWinterDRGiladiALara-AstiasoDet al. The spectrum and regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome. Cell (2016) 166(5):1231–46.e13. doi: 10.1016/j.cell.2016.07.043

  • CrossRef
  • Google Scholar

• 419

  HepworthMRMonticelliLAFungTCZieglerCGGrunbergSSinhaRet al. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature (2013) 498(7452):113–7. doi: 10.1038/nature12240

  • CrossRef
  • Google Scholar

• 420

  HepworthMRFungTCMasurSHKelsenJRMcConnellFMDubrotJet al. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria–specific CD4+ T cells. Science (2015) 348(6238):1031–5. doi: 10.1126/science.aaa4812

  • CrossRef
  • Google Scholar

• 421

  MorthaAChudnovskiyAHashimotoDBogunovicMSpencerSPBelkaidYet al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science (2014) 343(6178):1249288. doi: 10.1126/science.1249288

  • CrossRef
  • Google Scholar

• 422

  KruglovAAGrivennikovSIKuprashDVWinsauerCPrepensSSeleznikGMet al. Nonredundant function of soluble LTα3 produced by innate lymphoid cells in intestinal homeostasis. Science (2013) 342(6163):1243–6. doi: 10.1126/science.1243364

  • CrossRef
  • Google Scholar

• 423

  GotoYObataTKunisawaJSatoSIvanovIILamichhaneAet al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science (2014) 345(6202):1254009. doi: 10.1126/science.1254009

  • CrossRef
  • Google Scholar

• 424

  Le RouzicOPichavantMFrealleEGuillonASi-TaharMGossetP. Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations. Eur Respir J (2017) 50(4). doi: 10.1183/13993003.02434-2016

  • CrossRef
  • Google Scholar

• 425

  EbboMCrinierAVélyFVivierE. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol (2017) 17(11):665–78. doi: 10.1038/nri.2017.86

  • CrossRef
  • Google Scholar

• 426

  ArdainAPorterfieldJZKløverprisHNLeslieA. Type 3 ILCs in lung disease. Front Immunol (2019) 10:92. doi: 10.3389/fimmu.2019.00092

  • CrossRef
  • Google Scholar

• 427

  LindenAHoshinoHLaanM. Airway neutrophils and interleukin-17. Eur Respir J (2000) 15(5):973–7. doi: 10.1034/j.1399-3003.2000.15e28.x

  • CrossRef
  • Google Scholar

• 428

  Di StefanoACaramoriGGnemmiIContoliMVicariCCapelliAet al. T Helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol (2009) 157(2):316–24. doi: 10.1111/j.1365-2249.2009.03965.x

  • CrossRef
  • Google Scholar

• 429

  SuzukiMSzeMACampbellJDBrothersJFLenburgMEMcDonoughJEet al. The cellular and molecular determinants of emphysematous destruction in COPD. Sci Rep (2017) 7(1):1–9. doi: 10.1038/s41598-017-10126-2

  • CrossRef
  • Google Scholar

• 430

  von GarnierCFilgueiraLWikstromMSmithMThomasJAStricklandDHet al. Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract. J Immunol (2005) 175(3):1609–18. doi: 10.4049/jimmunol.175.3.1609

  • CrossRef
  • Google Scholar

• 431

  IwasakiA. Mucosal dendritic cells. Annu Rev Immunol (2007) 25:381–418. doi: 10.1146/annurev.immunol.25.022106.141634

  • CrossRef
  • Google Scholar

• 432

  JahnsenFLStricklandDHThomasJATobagusITNapoliSZoskyGRet al. Accelerated antigen sampling and transport by airway mucosal dendritic cells following inhalation of a bacterial stimulus. J Immunol (2006) 177(9):5861–7. doi: 10.4049/jimmunol.177.9.5861

  • CrossRef
  • Google Scholar

• 433

  VeresTZVoedischSSpiesETschernigTBraunA. Spatiotemporal and functional behavior of airway dendritic cells visualized by two-photon microscopy. Am J pathol (2011) 179(2):603–9. doi: 10.1016/j.ajpath.2011.04.039

  • CrossRef
  • Google Scholar

• 434

  RateAUphamJWBoscoAMcKennaKLHoltPG. Airway epithelial cells regulate the functional phenotype of locally differentiating dendritic cells: implications for the pathogenesis of infectious and allergic airway disease. J Immunol (2009) 182(1):72–83. doi: 10.4049/jimmunol.182.1.72

  • CrossRef
  • Google Scholar

• 435

  KimD-YSatoAFukuyamaSSagaraHNagatakeTKongIGet al. The airway antigen sampling system: respiratory m cells as an alternative gateway for inhaled antigens. J Immunol (2011) 186(7):4253–62. doi: 10.4049/jimmunol.0903794

  • CrossRef
  • Google Scholar

• 436

  ShaykhievRBalsR. Interactions between epithelial cells and leukocytes in immunity and tissue homeostasis. J leukoc Biol (2007) 82(1):1–15. doi: 10.1189/jlb.0207096

  • CrossRef
  • Google Scholar

• 437

  SoloffACBarratt-BoyesSM. Enemy at the gates: dendritic cells and immunity to mucosal pathogens. Cell Res (2010) 20(8):872–85. doi: 10.1038/cr.2010.94

  • CrossRef
  • Google Scholar

• 438

  HoltPGStricklandDHWikströmMEJahnsenFL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol (2008) 8(2):142–52. doi: 10.1038/nri2236

  • CrossRef
  • Google Scholar

• 439

  HammadHLambrechtBN. Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. J Allergy Clin Immunol (2006) 118(2):331–6. doi: 10.1016/j.jaci.2006.03.041

  • CrossRef
  • Google Scholar

• 440

  WhitesonKAgrawalSAgrawalA. Differential responses of human dendritic cells to metabolites from the oral/airway microbiome. Clin Exp Immunol (2017) 188(3):371–9. doi: 10.1111/cei.12943

  • CrossRef
  • Google Scholar

• 441

  Ezzati GiviMRedegeld FAFolkertsGMortazE. Dendritic cells in pathogenesis of COPD. Curr Pharm design (2012) 18(16):2329–35. doi: 10.2174/138161212800166068

  • CrossRef
  • Google Scholar

• 442

  TsoumakidouMDemedtsIKBrusselleGGJefferyPK. Dendritic cells in chronic obstructive pulmonary disease: new players in an old game. Am J Respir Crit Care Med (2008) 177(11):1180–6. doi: 10.1164/rccm.200711-1727PP

  • CrossRef
  • Google Scholar

• 443

  Van PottelbergeGRBrackeKRJoosGFBrusselleGG. The role of dendritic cells in the pathogenesis of COPD: liaison officers in the front line. COPD: J Chronic Obstructive Pulm Dis (2009) 6(4):284–90. doi: 10.1080/15412550903049124

  • CrossRef
  • Google Scholar

• 444

  VassalloRWaltersPRLamontJKottomTJYiESLimperAH. Cigarette smoke promotes dendritic cell accumulation in COPD; a lung tissue research consortium study. Respir Res (2010) 11(1):1–13. doi: 10.1186/1465-9921-11-45

  • CrossRef
  • Google Scholar

• 445

  Van PottelbergeGRBrackeKRDemedtsIKDe RijckKReinartzSMVan DrunenCMet al. Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD. Respir Res (2010) 11(1):1–21. doi: 10.1186/1465-9921-11-35

  • CrossRef
  • Google Scholar

• 446

  ObataTGotoYKunisawaJSatoSSakamotoMSetoyamaHet al. Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis. Proc Natl Acad Sci (2010) 107(16):7419–24. doi: 10.1073/pnas.1001061107

  • CrossRef
  • Google Scholar

• 447

  NeillDRWongSHBellosiAFlynnRJDalyMLangfordTKet al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature (2010) 464(7293):1367–70. doi: 10.1038/nature08900

  • CrossRef
  • Google Scholar

• 448

  YangDChenXWangJLouQLouYLiLet al. Dysregulated lung commensal bacteria drive interleukin-17B production to promote pulmonary fibrosis through their outer membrane vesicles. Immunity (2019) 50(3):692–706.e7. doi: 10.1016/j.immuni.2019.02.001

  • CrossRef
  • Google Scholar

• 449

  SegalLNClementeJCTsayJ-CJKoralovSBKellerBCWuBGet al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol (2016) 1(5):16031. doi: 10.1038/nmicrobiol.2016.31

  • CrossRef
  • Google Scholar

• 450

  PandiyanPBhaskaranNZouMSchneiderEJayaramanSHuehnJ. Microbiome dependent regulation of tregs and Th17 cells in mucosa. Front Immunol (2019) 10:426. doi: 10.3389/fimmu.2019.00426

  • CrossRef
  • Google Scholar

• 451

  RoundJLLeeSMLiJTranGJabriBChatilaTAet al. The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science (2011) 332(6032):974–7. doi: 10.1126/science.1206095

  • CrossRef
  • Google Scholar

• 452

  WangSCharbonnierL-MRivasMNGeorgievPLiNGerberGet al. MyD88 adaptor-dependent microbial sensing by regulatory T cells promotes mucosal tolerance and enforces commensalism. Immunity (2015) 43(2):289–303. doi: 10.1016/j.immuni.2015.06.014

  • CrossRef
  • Google Scholar

• 453

  TsujiMKomatsuNKawamotoSSuzukiKKanagawaOHonjoTet al. Preferential generation of follicular b helper T cells from Foxp3+ T cells in gut peyer's patches. Science (2009) 323(5920):1488–92. doi: 10.1126/science.1169152

  • CrossRef
  • Google Scholar

• 454

  KawamotoSMaruyaMKatoLMSudaWAtarashiKDoiYet al. Foxp3+ T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis. Immunity (2014) 41(1):152–65. doi: 10.1016/j.immuni.2014.05.016

  • CrossRef
  • Google Scholar

• 455

  ZhangMZhouQDorfmanRGHuangXFanTZhangHet al. Butyrate inhibits interleukin-17 and generates tregs to ameliorate colorectal colitis in rats. BMC gastroenterol (2016) 16(1):1–9. doi: 10.1186/s12876-016-0500-x

  • CrossRef
  • Google Scholar

• 456

  LiMOWanYYFlavellRA. T Cell-produced transforming growth factor-β1 controls T cell tolerance and regulates Th1-and Th17-cell differentiation. Immunity (2007) 26(5):579–91. doi: 10.1016/j.immuni.2007.03.014

  • CrossRef
  • Google Scholar

• 457

  KonkelJEZhangDZanvitPChiaCZangarle-MurrayTJinWet al. Transforming growth factor-β signaling in regulatory T cells controls T helper-17 cells and tissue-specific immune responses. Immunity (2017) 46(4):660–74. doi: 10.1016/j.immuni.2017.03.015

  • CrossRef
  • Google Scholar

• 458

  HapfelmeierSLawsonMASlackEKirundiJKStoelMHeikenwalderMet al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science (2010) 328(5986):1705–9. doi: 10.1126/science.1188454

  • CrossRef
  • Google Scholar

• 459

  BunkerJJFlynnTMKovalJCShawDGMeiselMMcDonaldBDet al. Innate and adaptive humoral responses coat distinct commensal bacteria with immunoglobulin a. Immunity (2015) 43(3):541–53. doi: 10.1016/j.immuni.2015.08.007

  • CrossRef
  • Google Scholar

• 460

  MacphersonAJGattoDSainsburyEHarrimanGRHengartnerHZinkernagelRM. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science (2000) 288(5474):2222–6. doi: 10.1126/science.288.5474.2222

  • CrossRef
  • Google Scholar

• 461

  LadjemiMZMartinCLecocqMDetryBNanaFAMoulinCet al. Increased IgA expression in lung lymphoid follicles in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2019) 199(5):592–602. doi: 10.1164/rccm.201802-0352OC

  • CrossRef
  • Google Scholar

• 462

  BunkerJJBendelacA. IgA responses to microbiota. Immunity (2018) 49(2):211–24. doi: 10.1016/j.immuni.2018.08.011

  • CrossRef
  • Google Scholar

• 463

  GoodKLBryantVLTangyeSG. Kinetics of human b cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol (2006) 177(8):5236–47. doi: 10.4049/jimmunol.177.8.5236

  • CrossRef
  • Google Scholar

• 464

  KaetzelCSRobinsonJKChintalacharuvuKRVaermanJ-PLammME. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc Natl Acad Sci (1991) 88(19):8796–800. doi: 10.1073/pnas.88.19.8796

  • CrossRef
  • Google Scholar

• 465

  MoorKDiardMSellinMEFelmyBWotzkaSYToskaAet al. High-avidity IgA protects the intestine by enchaining growing bacteria. Nature (2017) 544(7651):498–502. doi: 10.1038/nature22058

  • CrossRef
  • Google Scholar

• 466

  LindnerCThomsenIWahlBUgurMSethiMKFriedrichsenMet al. Diversification of memory b cells drives the continuous adaptation of secretory antibodies to gut microbiota. Nat Immunol (2015) 16(8):880–8. doi: 10.1038/ni.3213

  • CrossRef
  • Google Scholar

• 467

  MagriGComermaLPybusMSintesJLligéDSegura-GarzónDet al. Human secretory IgM emerges from plasma cells clonally related to gut memory b cells and targets highly diverse commensals. Immunity (2017) 47(1):118–34.e8. doi: 10.1016/j.immuni.2017.06.013

  • CrossRef
  • Google Scholar

• 468

  HaasAZimmermannKGrawFSlackERusertPLedergerberBet al. Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut (2011) 60(11):1506–19. doi: 10.1136/gut.2010.224774

  • CrossRef
  • Google Scholar

• 469

  OkamuraTGohdaEKohgeTYamamotoI. An increase in histone acetylation and IL-2 antagonizing the immunoinhibitory effect are necessary for augmentation by butyrate of in vitro anti-TNP antibody production. Biol Pharm Bullet (1999) 22(12):1288–92. doi: 10.1248/bpb.22.1288

  • CrossRef
  • Google Scholar

• 470

  AoshibaKNagaiA. Senescence hypothesis for the pathogenetic mechanism of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2009) 6(7):596–601. doi: 10.1513/pats.200904-017RM

  • CrossRef
  • Google Scholar

• 471

  HuertasAPalangeP. COPD: a multifactorial systemic disease. Ther Adv Respir dis (2011) 5(3):217–24. doi: 10.1177/1753465811400490

  • CrossRef
  • Google Scholar

• 472

  PackardTALiQZCosgroveGPBowlerRPCambierJC. COPD is associated with production of autoantibodies to a broad spectrum of self-antigens, correlative with disease phenotype. Immunol Res (2013) 55(1):48–57. doi: 10.1007/s12026-012-8347-x

  • CrossRef
  • Google Scholar

• 473

  Feghali-BostwickCAGadgilASOtterbeinLEPilewskiJMStonerMWCsizmadiaEet al. Autoantibodies in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 177(2):156–63. doi: 10.1164/rccm.200701-014OC

  • CrossRef
  • Google Scholar

• 474

  CosioMGGuerassimovA. Chronic obstructive pulmonary disease: inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med (1999) 160(supplement_1):S21–S5. doi: 10.1164/ajrccm.160.supplement_1.7

  • CrossRef
  • Google Scholar

• 475

  RichmondBWMansouriSSerezaniANovitskiySBlackburnJBDuRHet al. Monocyte-derived dendritic cells link localized secretory IgA deficiency to adaptive immune activation in COPD. Mucosal Immunol (2021) 14(2):431–42. doi: 10.1038/s41385-020-00344-9

  • CrossRef
  • Google Scholar

• 476

  HoggJCChuFUtokaparchSWoodsRElliottWMBuzatuLet al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med (2004) 350(26):2645–53. doi: 10.1056/NEJMoa032158

  • CrossRef
  • Google Scholar

• 477

  LeeSHGoswamiSGrudoASongLZBandiVGoodnight-WhiteSet al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med (2007) 13(5):567–9. doi: 10.1038/nm1583

  • CrossRef
  • Google Scholar

• 478

  FanerRCruzTCasserrasTLópez-GiraldoANoellGCocaIet al. Network analysis of lung transcriptomics reveals a distinct b-cell signature in emphysema. Am J Respir Crit Care Med (2016) 193(11):1242–53. doi: 10.1164/rccm.201507-1311OC

  • CrossRef
  • Google Scholar

• 479

  PolverinoFSeysLJBrackeKROwenCA. B cells in chronic obstructive pulmonary disease: moving to center stage. Am J Physiol-Lung Cell Mol Physiol (2016) 311(4):L687–L95. doi: 10.1152/ajplung.00304.2016

  • CrossRef
  • Google Scholar

• 480

  GosmanMMWillemseBWJansenDFLapperreTSvan SchadewijkAHiemstraPSet al. Increased number of b-cells in bronchial biopsies in COPD. Eur Respir J (2006) 27(1):60–4. doi: 10.1183/09031936.06.00007005

  • CrossRef
  • Google Scholar

• 481

  LitsiouESemitekolouMGalaniIEMorianosITsoutsaAKaraPet al. CXCL13 production in b cells via toll-like receptor/lymphotoxin receptor signaling is involved in lymphoid neogenesis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 187(11):1194–202. doi: 10.1164/rccm.201208-1543OC

  • CrossRef
  • Google Scholar

• 482

  BrusselleGDemoorTBrackeKBrandsmaCTimensW. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J (2009) 34(1):219–30. doi: 10.1183/09031936.00150208

  • CrossRef
  • Google Scholar

• 483

  SeysLJVerhammeFMSchinwaldAHammadHCunoosamyDMBantsimba-MalandaCet al. Role of b cell–activating factor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 192(6):706–18. doi: 10.1164/rccm.201501-0103OC

  • CrossRef
  • Google Scholar

• 484

  PolverinoFCosioBGPonsJLaucho-ContrerasMTejeraPIglesiasAet al. B cell–activating factor. an orchestrator of lymphoid follicles in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 192(6):695–705. doi: 10.1164/rccm.201501-0107OC

  • CrossRef
  • Google Scholar

• 485

  SullivanJ-LBagevaluBGlassCShollLKraftMMartinezFDet al. B cell–adaptive immune profile in emphysema-predominant chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2019) 200(11):1434–9. doi: 10.1164/rccm.201903-0632LE

  • CrossRef
  • Google Scholar

• 486

  LinSMaZHuangYSunYYiH. Chronic obstructive pulmonary disease is characterized by reduced levels and defective suppressive function of regulatory b cells in peripheral blood. Mol Immunol (2022) 141:87–93. doi: 10.1016/j.molimm.2021.11.007

  • CrossRef
  • Google Scholar

• 487

  BrandsmaC-AKerstjensHAvan GeffenWHGeerlingsMPostmaDSHylkemaMNet al. Differential switching to IgG and IgA in active smoking COPD patients and healthy controls. Eur Respir J (2012) 40(2):313–21. doi: 10.1183/09031936.00011211

  • CrossRef
  • Google Scholar

• 488

  JacobsMVerschraegenSSalhiBAnckaertJMestdaghPBrusselleGGet al. IL-10 producing regulatory b cells are decreased in blood from smokers and COPD patients. Respir Res (2022) 23(1):1–12. doi: 10.1186/s12931-022-02208-1

  • CrossRef
  • Google Scholar

• 489

  LanzilliGTraggiaiEBraidoFGarelliVFolliCChiapporiAet al. Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: effects on circulating T, b and NK cells. Immunol Lett (2013) 149(1-2):62–7. doi: 10.1016/j.imlet.2012.11.009

  • CrossRef
  • Google Scholar

• 490

  ChenFWuWJinLMillmanAPalmaMEl-NaccacheDWet al. B cells produce the tissue-protective protein RELMα during helminth infection, which inhibits IL-17 expression and limits emphysema. Cell Rep (2018) 25(10):2775–83.e3. doi: 10.1016/j.celrep.2018.11.038

  • CrossRef
  • Google Scholar

• 491

  CurtisJL. B cells caught in the act: class switching to IgA in lung lymphoid follicles in chronic obstructive pulmonary disease. Am Thorac Soc (2019) 199(5):548–50. doi: 10.1164/rccm.201810-1907ED

  • CrossRef
  • Google Scholar

• 492

  LadjemiMZLecocqMWeynandBBowenHGouldHJVan SnickJet al. Increased IgA production by b-cells in COPD via lung epithelial interleukin-6 and TACI pathways. Eur Respir J (2015) 45(4):980–93. doi: 10.1183/09031936.00063914

  • CrossRef
  • Google Scholar

• 493

  CurtisJL. B cells caught in the act: Class switching to IgA in lung lymphoid follicles in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2019) 199(5):548–50. doi: 10.1164/rccm.201810-1907ED

  • CrossRef
  • Google Scholar

• 494

  RobertsIS. Pathology of IgA nephropathy. Nat Rev Nephrol (2014) 10(8):445–54. doi: 10.1038/nrneph.2014.92

  • CrossRef
  • Google Scholar

• 495

  StaplesKJTaylorSThomasSLeungSCoxKPascalTGet al. Relationships between mucosal antibodies, non-typeable haemophilus influenzae (NTHi) infection and airway inflammation in COPD. PloS One (2016) 11(11):e0167250. doi: 10.1371/journal.pone.0167250

  • CrossRef
  • Google Scholar

• 496

  VeeramachaneniSBSethiS. Pathogenesis of bacterial exacerbations of COPD. Copd (2006) 3(2):109–15. doi: 10.1080/15412550600651347

  • CrossRef
  • Google Scholar

• 497

  BengoecheaJA. Secretory IgA and COPD: a new kid on the block? Am J Respir Crit Care Med (2011) 184(3):285–7. doi: 10.1164/rccm.201105-0821ED

  • CrossRef
  • Google Scholar

• 498

  MillaresLMartíSArdanuyCLiñaresJSantosSDorcaJet al. Specific IgA against pseudomonas aeruginosa in severe COPD. Int J Chron Obstruct Pulmon Dis (2017) 12:2807–11. doi: 10.2147/COPD.S141701

  • CrossRef
  • Google Scholar

• 499

  MurphyTFBrauerALAebiCSethiS. Antigenic specificity of the mucosal antibody response to moraxella catarrhalis in chronic obstructive pulmonary disease. Infect Immun (2005) 73(12):8161–6. doi: 10.1128/IAI.73.12.8161-8166.2005

  • CrossRef
  • Google Scholar

• 500

  SinghSNataliniJGSegalLN. Lung microbial-host interface through the lens of multi-omics. Mucosal Immunol (2022) 15(5):837–45. doi: 10.1038/s41385-022-00541-8

  • CrossRef
  • Google Scholar